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1. Introduction
1.1. Oculopharyngodistal Myopathy
Oculopharyngodistal Myopathy (OPDM, MIM #164310) was ﬁrst described by Sa-
tayoshi and Kinoshita in 1977 as an autosomal dominant muscle condition with onset
in late adulthood and symptoms of ptosis, slowly progressive dysphagia and predom-
inantly distal limb-girdle muscle weakness [1]. Although most reported families show
an autosomal dominant inheritance, patients from Japan [2], the Netherlands [3],
China [4] and Turkey [5] are reported with an autosomal recessive inheritance. To
this day, 82 patients from 34 unrelated families of diﬀerent ethnic backgrounds have
been reported, with an apparent accumulation of cases in Japan and Turkey. There
had been a discussion, whether OPDM is a clinicopathological distinct entity or a
variant of oculopharyngeal muscular dystrophy (OPMD; MIM #164300) [6] with
the majority of authors claiming, that OPDM is clinically distinguishable from sim-
ilar muscle conditions. Until the causative genetic changes are found, the diagnosis
has to be made based on clinical and histopathological changes as well as on the
exclusion of similar genetic disorders. Furthermore, until the genetic cause or causes
are found, it is not certain if variations in more than one gene are related to a single
distinct phenotype we call OPDM today.
1.1.1. Clinical Symptoms
There is great variability for the age of onset of OPDM, ranging from 7 to 66 years.
In general, Japanese patients tend to develop ﬁrst symptoms much later than in-
dividuals from other countries. Usually, a bilateral ptosis is the initial symptom,
followed by swallowing diﬃculties, dysarthria, ophthalmoparesis and predominantly
distal limb-girdle muscle weakness. Chinese Patients, however, usually present ﬁrst
with distal muscle impairment [4]. About half of the published cases show respi-
ratory muscle involvement with some of them needing nocturnal non-invasive posi-
tive pressure ventilation. Only two reported patients exhibited cardiac involvement
- common in other muscle conditions such as muscular dystrophies, myoﬁbrillar
myopathies, congenital myopathies and metabolic myopathies - namely hypertra-
beculation and myocardial thinning [7], [8]. CK-levels in those cases are normally
slightly increased ranging from normal to eight-fold of the upper limit [5]. Almost
1
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all examined individuals showed nonspeciﬁc myopathic changes in electromyography
such as reduced amplitude and duration of muscle unit potentials (MUPs) due to
the reduced number of functioning muscle ﬁbres. Some publications have reported
myotonic discharges [5], [9], [4], [10].
1.1.2. Histopathological ﬁndings
Light microscopy of all patients reported so far showed myopathic changes such as
ﬁbre size variation, angulated ﬁbres, internal nuclei, interstitial ﬁbrosis and fatty
connective tissues as shown in Figure 1.1. Rimmed vacuoles, seen in both ﬁbre
types and appearing with a red margin in Gomori-Trichrome staining, seem to have
a high sensitivity [6], [5] but low speciﬁcity in diagnosing OPDM. They can also
be present in similar muscle conditions like OPMD or inclusion body myositis [11].
Ragged-red ﬁbres or signs of inﬂammation were not seen in any of the patients.
Figure 1.1.: Haematoxylin and eosin staining, biopsy taken from tibialis anterior mus-
cle. (A)Non-speciﬁc myopathological changes with variation in ﬁbre size, increase in
connective tissue and increased number of internal nuclei. Also visible are rimmed
vacuoles (arrows) in angular muscle ﬁbres. (B) Foamy rimmed vacuoles in small and
larger muscle ﬁbres. (Figure taken from Durmus et al. 2011 [5])
Electron microscopy studies have shown a greater variation of ﬁndings. Some
authors report cytoplasmic ﬁlaments [2], [3], which is an unspeciﬁc ﬁnding in neuro-
muscular disorders. Myelin ﬁgures [5], [9] in rimmed vacuoles seem to be a common
ﬁnding in OPDM, subsarcolemmal masses of lipofuscin were only observed in one
patient [9]. Intranuclear aggregations of tubular ﬁlaments, thought to be speciﬁc
for OPMD, were found in two families [7], [10]. These changes are shown in Figure
1.2. In summary, it is hard to distinguish between OPDM and OPMD based on
histopathological analysis. Therefore, some experts argue that OPDM is a subcat-
egory of OPMD with normal GCG-repeats in the nuclear mRNA binding protein
PABPN1, which are causative for OPMD.
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Figure 1.2.: Electron microscopy lead citrate and uranyl acetate staining. (A)
Tubuloﬁlamentous inclusions in the nucleus. (B) Numerous myelin ﬁgures were ag-
gregated. (C) (magniﬁcation: x96.500) Cytoplasmic ﬁlaments which are located close
to rimmed vacuoles (the latter indicated by arrows). The ﬁlaments are 16-18 nm in
diameter. (Figure taken from Lu et al. 2008 and Uyama et al. 1998 [10], [2])
1.2. Exome Sequencing
1.2.1. The Concept
The human genome consists of around 3 Gb (giga-basepairs) [12] but only 1% of this
vast number constitutes the protein coding part we call the exome - i.e. the protein
coding regions. Nevertheless, it is the region where about 85% of all disease causing
mutations occur [13]. Before the introduction of whole exome sequencing (WES) ,
the common approach in order to identify the underlying genetic variation of inher-
ited diseases included performance of linkage analysis in families with known shared
genetic heritage, followed by Sanger-sequencing of the genomic region of interest or,
alternatively, a candidate gene approach. This is costly and time-consuming and
success in identifying disease underlying mutations has been varying [14]. Hence,
focussing on the exome is a reasonable approach when trying to identify mutations
in Mendelian disorders as this massively reduces time, computational capacity and
the problems with identifying a vast number of intronic and intergenic variants of
unknown signiﬁcance. In recent years, the hard- and software for WES have im-
proved immensely while costs and hands-on time have decreased, thus making it an
ideal method to target rare inherited conditions of unknown genetic cause. OMIM
(Online Mendelian Inheritance in Man) lists more than 6000 presumably monogenic
disorders but for more than two thirds of these the molecular basis has not yet been
detected [13]. Since the establishment of exome enrichment strategies in 2007 [15],
the ﬁrst genetic diagnosis based on whole-exome sequencing in 2009 [16] and the
ﬁrst identiﬁcation of a genetic cause of a Mendelian disorder in Miller syndrome
[17], many cases have been solved in this short period of time.
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1.2.2. Method
To perform whole-exome sequencing, the protein coding regions of the genome which
only comprise around 1% of the human genome have to be enriched and ampliﬁed.
This is followed by the sequencing step, usually done by modern massive parallel
high-throughput sequencing-by-synthesis machines. Figure 1.3 brieﬂy summarizes
the work ﬂow of whole-exome sequencing. There are three possible main principles,
by which exome enrichment can be carried out: By in-solution capture, by hybridis-
ation to an array or by polymerase chain reaction (PCR) . The hybridisation method
uses single stranded oligonucleotides attached to the surface of a chip. These are
complementary to the exonic regions of the human genome. The probe DNA is
sheared to create double stranded fragments and a universal priming sequence is
added. There fragments are then hybridized to the oligonucleotides on the array
and unhybridised DNA is washed away. The remaining fragments are ampliﬁed
by PCR and sequenced. Roche NimbleGen is the ﬁrst and most popular system
applying this method. [18]
The most common method for target enrichment, such as the exome, is in-solution
capture. Similarly, to the method described above, it uses a pool of custom oligonu-
cleotides attached to magnetic beads that can hybridize with the targeted region.
Next, they are ferromagnetically pulled down and washed followed by PCR ampli-
ﬁcation and sequencing. [20]
Quite recently, Life Technologies have improved the method of exome enrichment
by PCR and solved many of its problems, such as low read depth and coverage
and combines this with the advantages of being time-saving and needing as little
as 50 ng of template DNA. It is an in-solution capture method and uses primer
pairs for around 300.000 amplicons which are multiplexed in 12 pools of 24.000.
Each of the pools works as one individual multiplex PCR reaction and is then
combined for the sequencing reaction. The sequencing-by-synthesis in this kit works
by measuring H+-ions released during base incorporation as opposed to ﬂuorescence
or chemiluminescence as used in the most common sequencing systems.
The two most common other sequencing techniques were introduced by Illumina
and Roche (454 technique). In both cases, the sequencing library itself has to be
created by PCR-ampliﬁcation of the DNA-template. Roche then uses an emulsion
PCR to create millions of clonal ampliﬁcations that are then attached to sequencing
beads. This is followed by pyrosequencing, carried out in cycles. During each cycle,
only one of the deoxyribonucleotides is oﬀered. If it matches the base on the comple-
mentary strand, it gets incorporated and pyrophosphate is split oﬀ. Together with
adenosine phosphosulfate (APS) it forms ATP which then, when luciferin is added
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Figure 1.3.: Simpliﬁed work ﬂow of a whole-exome sequencing analysis. Adapted from
Lohmann et al. 2014, [19]
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forms oxy-luciferin and light in the presence of luciferase which can be detected with
a CCD (charge coupled device) -camera, as displayed in Figure 1.4
Figure 1.4.: Schematic illustration of pyrosequencing as used by the Roche 454 se-
quencers.
Illumina, however uses bridge PCRs to create locally diﬀerentiated clusters of
identical PCR amplicons. DNA and primers get attached to ﬂow cells and the two
oligonucleotides hybridize to form a bridge as shown in Figure 1.5. After a certain
number of PCR cycles, a cluster of amplicons forms. A step of denaturation leaves
single stranded templates anchored to the surface. The sequencing primer anneals
to the adaptor sequence of each DNA fragment and the sequencing can be done by
a technique called cyclic reversible termination. It uses deoxyribonucleotides which
contain a ﬂuorophore and a reversible blocking group. The four nucleotides have
four diﬀerent ﬂuorophores attached, emitting at diﬀerent wave lengths. In each cycle
the polymerase extends the strand by one base and the blocking group terminates
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DNA syntheses. Unbound nucleotides are washed away and the array is imaged
to determine the incorporated nucleotide. In a ﬁnal step, the blocking group gets
removed before a new cycle begins. (See ﬁgure 1.6)
Figure 1.5.: Schematic illustration of Illumina exome enrichment and ampliﬁca-
tion. Single DNA fragments and primers (red), complementary to the adaptor-
sequence (green), are attached to ﬂow cells. In each ampliﬁcation step, bridges
form and leave clusters of homogenous DNA fragments after the denaturation
step. A universal primer binds to the adaptors for the following sequencing re-
action (adapted from https://www.eurofinsgenomics.eu/de/eurofins-genomics/
produkt-faqs/next-generation-sequencing.aspx).
The common output is FASTQ ﬁles, which is a format for sharing both the se-
quencing read combined with a quality score for each base [21]. The read sequences
now need to be aligned, which means that each short read is mapped to a reference
genome. There is a large number of software tools available that all come with
advantages and disadvantages. The most important aspect in discussing diﬀerent
alignment algorithms is accuracy. When it comes to single nucleotide polymor-
phisms (SNPs) , SOAP is the most accurate aligner, followed by Bowtie [22], BWA
and Novoalign. Yet, SOAP fails to align any reads with indels greater than 6bp
which limits its use dramatically, considering, that the average pathogenic deletion
has a size of 10bp. Here Novoalign performs best, especially when it comes to greater
indels of 10-16bp. BWA only produces accurate alignment when a threshold value
to remove unfavourable reads is introduced. Another important aspect is runtime.
Here, Novoalign performs very good, even when processing large genomes. How-
ever, Bowtie performs better for high sequencing depth and therefore greater read
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Figure 1.6.: Schematic illustration of sequencing by cyclic reversible termination. Se-
quencing of generated clusters is performed by DNA-replication with reversible dye
terminators. These are deoxyribonucleotides carrying diﬀerent ﬂuorophores for the
4 bases respectively and a blocking group. Since the blocking group terminates
DNA synthesis the strand is extended only by one labelled nucleotide. The sur-
face is then washed to remove non-incorporated nucleotides. In order to identify
incorporated nucleotide, the ﬂuorescent signal is analysed. Subsequently, the ﬂuo-
rophore and the blocking group is cleaved from the nucleotide and the next cycle
begins. (adapted from https://www.eurofinsgenomics.eu/de/eurofins-genomics/
produkt-faqs/next-generation-sequencing.aspx)
counts. All in all, researchers have to choose the alignment program according to
their computational infrastructure as well as their scientiﬁc aims and questions.
Post-alignment processing of the data comprises removal of duplicated reads, indel
(insertion or deletion) realignment for a better detection of insertions and deletions,
a base quality score recalibration and ﬁnally the variant calling [23]. Studies in
the past have demonstrated substantial disagreement between variant calls made
by diﬀerent pipelines. This illustrates the problematic nature of interpreting the
data [24][25][26]. Especially detection of indels is still challenging even though al-
gorithms have improved over the years. Common platforms are genome analysis
toolkit (GATK) [27], Dindel [28], Platypus [29], SAMtools [30] as well as VarScan
[31] for indels. The easiest way of detecting variants is by mapping reads to a ref-
erence genome and then scanning for systematic diﬀerences [32]. A slightly more
complex way is to reconstruct haplotypes that are well supported by the data to
identify true variants [33]. The advantage is, that this approach ensures semantic
consistency, which means that there can be no logic contradiction in variant calling
such as diﬀerent bases on the same allele in a detected variant. However, mapping
algorithms also have a number of disadvantages. Firstly, this method focuses on
SNPs and very short indels which leads to errors around larger indels or other vari-
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ants. Secondly, it often fails in regions of high similarity where misalignment creates
a systematic error [29].
Another approach when aiming to avoid these limitations is a reference-free as-
sembly. It does not rely on a reference genome and is therefore variant agnostic. It
also copes well with diﬃcult to align regions and reconstructs the haplotypes to call
the variants making this algorithm highly speciﬁc. Especially indels are detected
more sensitively. However, it requires high computational power and has a lower
sensitivity for SNPs compared to mapping algorithms [34]. In addition, some variant
callers also borrow information across a number of samples to support a change in
one sample, if it matches the information contained in many others. Conclusively,
a weakly conﬁdential variant can be called if it is conﬁdently identiﬁed in another
sample or samples. [29].
Depending on alignment and variant calling programs, one is left with around
50,000-100,000 variants from whole exome sequencing including intronic, intergenic
and changes found in the untranslated regions (UTRs) of which around 20,000 are
on-target meaning in exonic regions [23]. Annotation programs are used to add
information such as genomic feature, gene symbol, exonic function and amino acid
change of each variant. The program Annovar, that was used in this project, also
adds information from dbSNP, 1000genomes and ESP6500 for assessing the minor
allele frequencies, integrates data retrieved from Phylop and Genomic Evolutionary
Rate Proﬁling (GERP) and employes diﬀerent tools to predict the pathogenicity of
variants.
These called and annotated variants then have to go through a ﬁltering pipeline
to reduce this high number to just a few candidate variants. The ﬁltering steps are
based on certain assumptions: First, the disease causing variant is rare, meaning only
present in aﬀected individuals. Second, only homozygous or heterozygous mutations
in one single gene are required to cause the observed phenotype. Third, these
mutations are 100% penetrant and have a large eﬀect size usually aﬀecting protein
sequence (insertions/deletions as well as missense, nonsense, frameshift or splice-
site aberrations). The assumption of a high penetrance is needed when interpreting
allele frequencies. Variants with a small eﬀect size usually have a higher frequency
and are associated with polygenic conditions such as diabetes. Therefore, ﬁltering
for indels and nonsynonymous, nonsense or splice-site changes and for those with a
minor allele frequency of less than 1% is usually the ﬁrst step [35]. Depending on
the project, variants of aﬀected individuals from one family can then be intersected
to see, which are present in all and excluded if they are also found in healthy family
members. Finally, the number can be further reduced based on the pattern of
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inheritance. To give an example, heterozygous  but not compound heterozygous
 as well as X-chromosomal variants can be excluded for an autosomal recessive
model.
1.2.3. Limitations
Even though WES provides a fast and relatively aﬀordable method, there are a
couple of limitations when trying to detect disease causing variants. Around 15%
of all known causative mutations for Mendelian conditions cannot be found within
the protein coding regions. These variants comprise for example mutations in the
promoter regions, in the introns which form cryptic splice acceptor sites or in the
untranslated regions. It is also possible, that variants in non-coding genes might
aﬀect cellular pathways and are therefore pathogenic. These cases are diﬃcult as
researchers usually spend much time with non-causative, rare variants which segre-
gate with the disease and try to prove their pathogenicity. Additionally, the coverage
is not yet satisfactory. Especially GC-rich regions are hard to enrich resulting in poor
read depth as well as the problem that some regions are not covered at all [36], [35].
Furthermore, duplicated regions such as pseudogenes usually cause a large number
of false positive calls as the alignment programs map these reads to all similar re-
gions and consequently, the diﬀerences are called as genomic changes. This can be
problematic for scientists when the list of candidate genes after the ﬁltering steps is
unsatisfactory because one cannot dismiss the possibility that the exonic pathogenic
variant is simply not covered. Even if the coverage would be 100%, one would still
face diﬃculties with copy number variations and larger insertions or deletions. Copy
number variations are usually undetectable by WES, as read depth varies a lot in
diﬀerent chromosomal regions and indels are a common cause, why reads cannot
be aligned as they diﬀer too much from the reference sequence. If a variant in a
gene, which is not yet annotated was disease causing, it would either not be en-
riched before sequencing or ﬁltered out in the bioinformatic pipeline [13]. On top of
this, one often faces a large number of possible disease causing variants. Especially
with smaller families and dominant models it is then hard to decrease this number
by linkage analysis or homozygosity mapping. These variants are often diﬃcult to
interpret [19]. Also, when detecting changes that are likely disease-causing, WES
cannot prove that a speciﬁc variant underlies the condition. Often it is then diﬃcult
to prove pathogenicity [35]. Usually, researchers try to ﬁnd mutations in the same
gene of other aﬀected individuals from diﬀerent families. If that is not possible,
e.g. in very rare diseases, it is necessary to look at cell and animal models to ﬁnd
the pathomechanism. Also, this problem harbours a second challenge: It can be
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easy to fall for a compelling but false causative variant when being confronted with
a large number of rare, protein altering genetic changes. This eﬀect is called the
narrative-potential of human genomes [37], [38]. Conclusively, researchers have to
be careful when claiming an association between genetic variants and disease and
consider certain guidelines such as these published by MacArthur et al. in 2014 [39].
Taken together, the limitations of whole exome sequencing only result in a success
rate of around 25% [40], [41].
1.2.4. Ethical Implications
In addition, researchers have to consider ethical implications, when using WES.
Some of these are rather theoretical but still have to be discussed, others occur in
everyday laboratory practice. Most importantly, there are no generally accepted
guidelines determining how to proceed, when detecting pathogenic genetic variants
like mutations in BRCA1, commonly causing breast- and other gynaecological can-
cers. Green et al. from the American College of Medical Genetics and Genomics
(ACMG) have published a list of 56 genes and suggested to inform the patients when
detecting mutations in one of these [42]. These genes are usually associated with
treatable/curable conditions, nevertheless this topic is still subject of debate. Yet,
informing the index patient about an important pathogenic variation is diﬃcult as
relatives who have a right not to know and never gave their consent to the project
might also be aﬀected. Most problems, however, deal with data protection. DNA
contains a lot of information which may be of interest for insurers, employers or the
police. Once it is sequenced and decoded it is hard to tell what is going to happen
in the future. Some sequences from WES and WGS can even be downloaded from
open access libraries and their future use is unspeciﬁed [14]. DNA harbours not only
information of the individual who has given informed consent to publishing the data
but also of all his relatives as these share some of his variants[13]. It might even
be possible to identify this individual based on the information from his DNA [14].
In conclusion, it is diﬃcult to obtain informed consent since it cannot be predicted
what information is gathered from the genomic sequence and how it may be used
in the future [43], [44]. However, when dealing with rare diseases, research is often
the only hope for patients to get a genetic diagnosis. This is important for them
due to implications for relatives as well as family planning. In some rare cases, a
correct genetic diagnosis also poses treatment options such as in Brown-Vialetto-
Van Laere syndrome where high dose riboﬂavin substitution results in a tremendous
improvement of symptoms [45]
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This study aims to identify the causative genetic variant responsible for OPDM.
The ﬁrst descriptions of this disease entity have been published many years ago [1]
[46] and all eﬀorts to ﬁnd the underlying mutations up to the present have been
unsuccessful. Patients and their families suﬀer tremendously from OPDM as this
condition aﬀects their ability to perform everyday tasks, eating, swallowing, walking
and eventually breathing. It also causes high costs for public health care or insurers,
so it is an important task to take the next step to provide support for the patients
and identify the condition's genetic cause. Most interestingly, diﬀerent inheritance
patterns and phenotypes have been reported, indicating that a complicated patho-
mechanism might be underlying [5], [7], [3]. A similar condition, OPMD, is caused
by a repeat expansion resulting in a dominant or recessive pattern of inheritance
depending on the number of additional triplets [11]. Finding the causative mutation
in OPDM would answer a number of questions such as whether this condition is a
genetically homogeneous disease and what the underlying pathomechanism is. De-
pending on the disease mechanism researchers could establish diagnostic algorithms
and eventually ﬁnd a treatment as has been the case in Pompe's Disease where the
defective enzyme alpha glucosidase can be substituted intravenously [47]. Also, the
knowledge that a certain mutation results in a speciﬁc phenotype can provide in-
formation on cellular and tissue physiology. Therefore this study tried to map the
disease locus using linkage analysis, homozygosity mapping and haplotyping in pre-
viously reported families from Turkey [5]. In order to identify the mutation causing
OPDM whole exome sequencing was carried out for 2 patients from a large dominant
family, 3 patients from a recessive family (both from Turkey [5]) and unpublished
patients from Canada, Finland and the United Kingdom. Candidate mutations were
evaluated by segregation analyses in the corresponding families as well as tests for
their occurrence in ethnically matched control individuals.
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3.1. Patients and Controls
Patients were assessed by their referring clinicians and genomic DNA was sent to the
Institute of Genetic Medicine, Newcastle with the patient's informed consent. DNA
from 70 ethnically matched healthy individuals was provided by the Friedrich-Baur-
Institut der Medizinischen Fakultät an der Neurologischen Klinik und Poliklinik der
LMU München. All studies have been approved by the local ethics committee in
Newcastle-upon-Tyne, UK.
3.2. Chemicals
Chemicals used can be found in table 3.1.
3.3. Molecular Biological Methods
3.3.1. Quantiﬁcation of Nucleic Acid Concentrations
Two diﬀerent systems were used to determine DNA concentrations. For larger
sample numbers the Nanodrop® spectrophotometer (Thermo Scientiﬁc), using an
ultraviolet-absorbance method, was used according to the manufacturer's instruc-
tion [48]. A fast alternative for smaller sample quantities is the Qubit® system (Life
Technologies) that applies ﬂuorescent dyes to quantify DNA concentrations.
3.3.2. Polymerase Chain Reaction
3.3.2.1. The Main Principle
Introduced by Karl Mullis in 1983, the polymerase chain reaction (PCR) is a fast
and cheap biochemical process to amplify a target genomic DNA sequence [49], [50].
The method relies on thermal cycling, consisting of cycles to separate the two DNA
strands, for the annealing of the sequence speciﬁc primers and the elongation by a
heat-stable DNA polymerase (Usually isolated from Thermus aquaticus).
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Chemical Supplier
Agarose Sigma-Aldrich
Tris base Sigma-Aldrich
Glacial acetic acid Sigma-Aldrich
EDTA Sigma-Aldrich
Safeview abm
Taq polymerase Molzym
MgCl PCR enhancer Molzym
dNTPs ThermoFisher
Pfu polymerase ThermoFisher
Primers MWG Euroﬁns
Restriction endonucleases New England BioLabs (if not stated otherwise)
Nuclease-free water Qiagen
EB-Buﬀer Qiagen
Acrylamide/Bis-acrylamide Sigma-Aldrich
TEMED Sigma-Aldrich
Ammonium persulfate Sigma-Aldrich
Ethidium bromide Sigma-Aldrich
Boric acid Sigma-Aldrich
Table 3.1.: Chemicals used in this study and the supplying companies.
Double distilled water 35 µl
10 mM dNTP mix 2 µl
10X Moltaq PCR buﬀer 5 µl
Moltaq PCR enhancer 4 µl
Forward primer at 50 pmol/µl 1 µl
Reverse primer at 50 pmol/µl 1 µl
Genomic DNA template at 100 ng/µl 1 µl
Moltaq Polymerase 1 µl
50 µl
Table 3.2.: Amounts of chemicals used for a standard PCR with a Taq-polymerase
3.3.2.2. Standard Protocol
Standard PCR was done using the Moltaq® Taq Polymerase (Molzyme) with the
amount of reagents which are listed in table 3.2 on page 14.
Standard PCR was performed in a Sensoquest® thermal cycler according to the
protocol found in table 3.3.
The melting temperature of primers increases with higher GC content and length.
It was calculated with the UCSC In-Silico-PCR software (https://genome.ucsc.
edu/cgi-bin/hgPcr) and the annealing temperature was adjusted depending on
the primer melting temperature.
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1. 94◦C: 5min Denaturation
2. 40 cycles
(1) 94◦C: 15s Separation of DNA strands
(2) 52-62◦C: 30s Primer annealing
(3) 72◦C: 2min DNA elongation
3. 72◦C: 7min Final elongation
Table 3.3.: Standard PCR-cycler settings with 40 cycles.
Acrylamide/Bis-acrylamide, 30% solution 4,8 ml
Water 4,8 ml
5x TBE buﬀer 2,4 ml
10% ammonium persulfate 200 µl
TEMED (Tetramethylethylendiamine) 10 µl
Table 3.4.: Protocol for casting polyacrylamide gels.
3.3.2.3. Modiﬁcation of standard PCR protocol
The Phusion ® High-Fidelity DNA Polymerase (New England Biolabs) was used for
target sequences with a high GC content or repeat-rich parts of the DNA according
to the manufacturer's instructions.
3.3.2.4. PCR Primers
PCR Primers were designed using primer3 (http://primer3.ut.ee/) based on the
hg19/GRCh37 assembly (http://genome.ucsc.edu/cgi-bin/hgNear), introduced
in 2009. They were synthesised by Euroﬁns MWG Operon, Ebersberg, Germany
using a HPSF (High Purity Salt Free) puriﬁcation protocol. A list of all primers
used can be found in the addendum (A.1 on page 93).
3.3.2.5. Gel Electrophoresis
1%-3% agarose gels were used for electrophoreses depending on the PCR prod-
uct's length. Standard agarose concentration for PCR reactions was 2%. The elec-
trophoresis was done in 1X TAE (Tris-acetate-EDTA) buﬀer. DNA was made visible
with Safeview (NBS biologicals). TAE was made in 10x stock solutions using 48.4 g
of Tris base [tris(hydroxymethyl)aminomethane], 11.4 ml of glacial acetic acid (17.4
M) and 3.7 g of EDTA, disodium salt in 1l of deionised water.
To determine the length of microsatellites 12% polyacrylamide gels were cast
according to the following protocol:
The gels were run in a vertical electrophoresis system and 1X TBE buﬀer. 10X
TBE stock solution was made using 108 g Tris, 55 g Boric acid, 9.3g EDTA and vol-
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ume was adjusted to 1 liter using deionised water. DNA was stained with ethidium
bromide according to the manufacturer's instructions.
3.3.3. PCR DNA Clean-up
DNA was either puriﬁed directly after the PCR using the QIAquick PCR Puriﬁcation
Kit or extracted from agarose gels using the QIAquick Gel Extraction Kit (both
Qiagen). 96-well plate PCR products were puriﬁed using the GenEluteTM 96 Well
PCR Clean-Up Kit (Sigma-Aldrich) according to standard protocol.
3.3.4. Cleavage of DNA with Restriction Endonucleases
Whenever possible and reasonable, restriction endonucleases were used for segre-
gation analysis of variants. For DdeI (Promega), 3µl of the supplied 10X buﬀer
D, 25µl water and 20 units in 2µl of the restriction enzyme were added to puri-
ﬁed PCR products and incubated at room temperature overnight. BsrDI -digest
was performed with 15µl puriﬁed PCR-products, 2µl 10X Buﬀer 2, 2µl 10X BSA
(Bovine Serum Albumin) as well as 5 units in 1µl restriction enzyme and incubated
for 2 hours at 65◦C. Digested DNA fragments were analysed on a 3% agarose gel.
3.3.5. DNA Sequencing and Sequence Analysis
Sequencing was done by Euroﬁns MWG Operon (Ebersberg, Germany) by cycle
sequencing, a modiﬁcation of Sanger sequencing. Sanger sequencing, ﬁrst introduced
in 1977 [51] uses the chain-termination method with ﬂuorescently or radioactively
labelled dideoxynucleotides (ddNTP). Cycle Sequencing however uses a heat-stable
polymerase and ﬂuorescently labelled ddNTPs emitting at diﬀerent wavelengths
and can therefore be performed in one tube with much less template DNA. The
electrophoresis is done in modern 96-capillaries sequencers.
The results were analysed with Chromas (http://chromas.software.informer.
com/) and BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
3.4. Bioinformatic methods
3.4.1. SNP-Array
SNP-arrays for 36 aﬀected and unaﬀected individuals from 8 Turkish families were
done by Source BioScience (Nottingham, UK). Each sample was normalised to a con-
centration of 50ng/µl. 200ng (4µl) of each normalised sample was ampliﬁed and sub-
sequently prepared for hybridisation (fragmentation, precipitation, re-suspension).
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The samples were hybridised to Inﬁnium II Human Linkage-12 arrays from Illumina
for 24 hours. Following hybridization, the Inﬁnium arrays were stained, washed and
ﬁnally scanned.
3.4.2. Linkage Analysis
The program Merlin was used to perform parametric multipoint linkage analyses
[52]. Linkage analyses were carried out for each individual family as well as for
all families together using a dominant, a co-dominant and a recessive model. The
aﬀection status of the youngest generation in Family 1 (see ﬁgure 4.1 on page 22
for pedigree) was deﬁned as unknown to prevent the result of false positive or
negative high linkage loci. Merlin requires 4 input-ﬁles, a data ﬁle (parametric.dat),
a pedigree ﬁle (parametric.ped), a map ﬁle (parametric.map) and a model ﬁle (para-
metric.model). The data ﬁle contains all the single nucleotide polymorphisms that
the linkage analysis is based on. The map ﬁle links these markers to positions on
each chromosome in cM (CentiMorgan). The pedigree ﬁle combines information
from all patients namely their aﬀection status, their gender, their generation and
their parents. To calculate the LOD (logarithm of odds)- score for diﬀerent patterns
of inheritance, a model ﬁle is used to provide data about the estimated penetrance
and the minor allele frequency of the mutation (For example input ﬁles see ﬁgure
A.2 on page 104 in the addendum.). To verify that input ﬁles are being interpreted
correctly, the program Pedstats is used [53] by prompting the following command
in DOS :
prompt> pedstats -d parametric.dat -p parametric.ped
If the pedstats output produced a correct summary of the families, merlin was used
to perform a parametric linkage analysis by prompting the following command:
prompt> merlin -d parametric.dat -p parametric.ped -m parametric.map
model parametric.model step 3 pdf
The step 3 option of the Merlin program was used, which adds an computed cal-
culation of the LOD-score at three steps between two consecutive markers. This
improves the analysis as the LOD-score tends to decrease around marker locations.
By adding pdf the data is shown in pdf ﬁles. All input ﬁles were created individu-
ally for each chromosome and for diﬀerent combinations of families. Genetic linkage
is indicated by a so called LOD score, which is the logarithm (base 10) of odds of
the likelihood of obtaining the test data if the two loci are linked compared to the
likelihood of observing the same data purely by chance [54]. By convention, a LOD
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score greater than 3 is considered evidence for linkage whereas a LOD-score of -2 is
considered an exclusion of linkage.
3.4.3. Homozygosity Mapping
Homozygosity mapping was performed based on the data from SNP-arrays and
Exome-Sequencing of individuals II/2, II/3 and II/5 using the program Homozy-
gositymapper (http://www.homozygositymapper.org/) [55]. This web-based pro-
gram stores marker data in a database into which SNP genotype ﬁles can be directly
uploaded. The ﬁles to be uploaded must be tabular with the samples as columns
and the SNPs as rows. Genptypes were written as follows: AA for wildtype; AB
for heterozygous variant; BB for homozygous variant and  if this SNP has not
been detected. Doing homozygosity mapping with exome sequencing data is not rea-
sonable as homozygous wildtype polymorphisms are not being detected by variant
calling programs. In consequence, one can not diﬀerentiate between homozygosity
for the wildtype allele and lack of alignment for this region. In these cases, the geno-
type was declared unknown if the polymorphism was called in one or two siblings.
In order to receive better results the program was provided with 14 control sam-
ples. Genotype data was downloaded from the website of the International Hapmap
Project (http://hapmap.ncbi.nlm.nih.gov/downloads/index.html.en). Unfor-
tunately, there is data from only a few ethnic groups and none perfectly matches the
background of the cohort the study at hand is based on. Due to the fact, that Turk-
ish people share a majority of their haplogroups with their caucasian neighbours,
Italian individuals were chosen as a control group.[56] Default settings were used in
Homozygositymapper and the built-in candidate gene search engine GeneDistiller
(http://www.genedistiller.org.) [57] was used to analyse genes in homozygous
regions. An excel spreadsheet with information on the genes, their expression in
skeletal muscle and information from the OMIM database [58] found inside ho-
mozygous regions was downloaded from the website and further analysed. Lists
of genes from the SNP genotyping array and the exome sequencing data were both
concatenated and intersected to retrieve the maximum as well as most likely number
of candidate genes.
3.4.4. Microsatellite analysis
Microsatellite analysis was done using Simple Sequence Length Polymorphisms
(SSLPs) on Chromosome 10. These markers were selected based on the informa-
tion found on UniSTS (http://www.ncbi.nlm.nih.gov/unists) a database listing
sequence tagged sites (STSs) . STSs are deﬁned by PCR primer pairs and are asso-
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ciated with additional information such as genomic position, genes, and sequences.
The markers listed in table 3.5 on page 19 were ampliﬁed using ﬂuorescently la-
belled primers and their length was determined in capillaries in the laboratory of
Professor Angela Hübner, Klinik- und Poliklinik für Kinder- und Jugendmedizin,
TU-Dresden, Germany.
Marker Position on Position
Genethon Map: (cM) in Mb
D10S1787 70,90 49,8
D10S1793 70,90 50,1
D10S1766 72,00 50,7
D10S196 72,50 52,1
D10S568 74,20 53,7
D10S1643 77,00 55,3
D10S1756 78,40 59,1
D10S589 81,70 61,5
D10S1652 83,30 64,4
D10S561 83,30 65,1
D10S1743 84,90 67,4
D10S1665 92,20 71,3
D10S1688 94,00 72,6
D10S1650 95,60 73,3
D10S1730 103,20 78,9
D10S201 105,90 81,0
D10S1777 105,90 81,1
D10S1686 109,20 85,6
Table 3.5.: List of microsatellites and their genomic position used for haplotype anal-
yses.
3.4.5. Whole Exome Sequencing
3.4.5.1. Target enrichment and sequencing
Exome sequencing for Patients I/5 (OPDM1) and I/10 (OPDM2) was done by Eu-
roﬁns MWG Operon (Ebersberg, Germany) based on the in-solution hybridization
Agilent SureSelect Exome kit with Illumina HiSeq 2000 sequencing. DNA from pa-
tients OPDM 3 - 8 were sent to Otogenetics (Atlanta, USA) for exome sequencing.
The Agilent V4 51Mb kit was used for target enrichment and sequencing was done
on an Illumina HiSeq 2000 sequencer.
3.4.5.2. Bioinformatic workﬂow
The raw data was downloaded from the company's servers as FASTQ ﬁles and
aligned to the hg19 assembly using programs working with various algorithms. This
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was done by the Burrows-Wheeler Aligner (BWA) and Bowtie, both using a FM-
index as well as Novoalign and MOSAIK, both hashing the reference [59]. SAMtools
was used to create a sorted BAM ﬁle. Picard, a program that comprises Java-based
command-line utilities that manipulate SAM ﬁles, was used to remove duplicate
reads to decrease the number of false positive heterozygous calls. SAMtools was
used to create a BAI ﬁle and SNVs were called by VarScan whereas indels were
called by Dindel. The calls were ﬁltered for variants which are 'on-target' (Truseq
62Mb target coordinates +/- 500bp), seen on both DNA strands and for a minimum
coverage of 5. SNVs found in more than 25% of the reads were declared heterozy-
gous, when found in more than 85% they were considered homozygous. Finally,
Annovar was used for gene based annotation of the changes. Given a list of variants
from whole-exome or whole-genome sequencing, it generates an Excel-compatible
ﬁle with gene annotation, the nucleotide- as well as the amino acid change, SIFT
scores [60], PolyPhen2 scores [61], LRT scores [62], MutationTaster scores [63], Phy-
loP conservation scores [64], GERP++ conservation scores, dbSNP identiﬁers, 1000
Genomes Project allele frequencies, ESP 6500 exome project allele frequencies and
other information. All variants were ﬁltered for those with a minor allele frequency
of less than 1% according to dbSNP (http://www.ncbi.nlm.nih.gov/SNP/), 1000
Genomes Project (http://www.1000genomes.org/) and the Exome Variant Server
(http://evs.gs.washington.edu/EVS/) as well as the Newcastle University In-
house MAF list. Any changes that were not found in exonic regions, the UTRs or
putative splice site mutations were ﬁltered out together with those in duplicated
regions (>92% similarity). Variants found in samples OPDM1 and OPDM2 as
well as OPDM 3 - OPDM 5 were intersected and analysed.
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4.1. Clinical Findings and Pedigrees
Most of the patients that were subject of the study at hand, come from a region
at the Black Sea in Turkey and were assessed in Istanbul at the Department of
Neurology (as described by Durmus et al. [5]). These 47 patients derive from 9
unrelated families whose pedigrees can be found in ﬁgure 4.1. However, aﬀection
status of individuals I/14 and I/15 could not ﬁnally be determined by the clinicians
as they were very young when the study was performed [5]. Therefore, they were
not considered in the linkage- and the haplotype analysis. Apparently, Families 1,
3, 4, 6 and 8 show a dominant pattern of inheritance, whereas Families 2 and 7 are
clearly recessive. The pedigree of Family 5 however implies incomplete penetrance
with an underlying dominant inheritance, as X-chromosomal dominant heredity or
a mitochondrial disease can be excluded due to the unaﬀected male conductor in the
third generation. OPDM in the single patient from Family 9 could occur sporadi-
cally or be caused by either a recessive mutation or a dominant one with incomplete
inheritance. OPDM-patient DNA was also provided by Dr Tanya Stojkovic in Paris,
France, Professor Dotti in Siena Italy ([9]), Professor Bjarne Udd in Tampere, Fin-
land, Professor Bernard Brais in Montreal, Canada, from Professor Patrick Chinnery
in Newcastle-upon-Tyne, UK and from Dr Paul Maddison in Nottingham, UK. Un-
fortunately, clinical data was not provided for any of the non-Turkish and non-Italian
patients but a clinical diagnosis and a genetic exclusion of other common neuromus-
cular disorders with a similar phenotype like Oculopharyngeal Muscle Dystrophy
was conﬁrmed.
4.2. Linkage Analysis
Parametric linkage analysis was performed based on SNP genotyping array data
(Inﬁnium II Human Linkage-12 array by Illumina) as described in chapter 3.4.2 on
page 17. It was done for each of the Families 1, 2, 3, 5, 6 and 8 individually as
well as all families 1-9 together. Also single families have been excluded to see how
this aﬀects the LOD-score. If it was to drop in a high linkage region this would
be a lead that OPDM might be caused by mutations in diﬀerent genes in diﬀerent
21
4. Results
Figure 4.1.: Pedigrees of 9 Turkish families aﬀected by oculopharyngodistal myopathy.
Adapted from Durmus et al. 2011 [5]
families. Figures 4.2 and 4.3 summarise the most important ﬁndings. For no other
chromosome apart from chromosome 2 and 10 a LOD-score greater than 1.0 has
been observed for any combination of families. For a recessive model, Family 2
shows a region around markers at 150cM where the LOD-score reaches 1.5 which
is signiﬁcant, considering that only 5 individuals have been genotyped. However,
this region can almost certainly be excluded as one shared disease locus for all
families because the LOD-score reaches -2 for markers at this position in Family
1. This is reﬂected in the linkage analysis of all families where the LOD-score is 0.
Nevertheless, if all but Family 1 are considered, this increases the LOD score for
this region on chromosome 2 beyond 1.7 indicating that OPDM in other families
might also be caused by a mutation in this region. The linkage peak in Family 1 on
chromosome 2 for a recessive model does not have to be of concern as the pattern
of inheritance is clearly dominant. For a dominant model only chromosome 10
exhibited a positive linkage. If a parametric linkage analysis for the largest clearly
dominant Family 1 is performed, the resulting LOD-score on chromosome 10 is
surprisingly low with values of around 1. Similarly, the LOD-score does not exceed
1 in Family 2 for this region. However, if all families are analysed together, the
LOD-score almost reaches 3 but it stays at values between 1,5 and 2, when Family
1 is excluded. This implies that the disease locus for families showing a dominant
inheritance could be successfully linked since the addition of other families increased
the linkage score considerably. The relatively high linkage on chromosome 10 for
22
4. Results
a recessive model was interpreted to be a by-product of the correctly mapped area
of interest in some families. Conclusively, the area at around 100cM - which is
approximately at the genomic position Chr10:80,000,000 - was considered to be the
most likely disease locus for dominant families.
4.3. Homozygosity Mapping
Given a high linkage to chromosome 2 for Family 2 which shows a recessive pattern of
inheritance, homozygosity mapping was used to further map the disease locus. The
web-based program was used as described previously in chapter 3.4.3 on page 18. It
does not only detect homozygous regions but also combines them with information
on allele frequency to provide an estimation score how likely the disease causing gene
is to be found in a region. For example, if an SNP has a very low frequency and
both alleles are wildtype in all aﬀected individuals, this would result in a lower score.
However, a very rare homozygous polymorphism would result in high scores. Figure
4.4 on page 26 shows results from homozygosity mapping from both SNP genotyping
array (A)(Individuals II/1, II/2, II/3, II/4 and II/5) and exome sequencing data (B)
(Indiciduals II/2, II/3 and II/5) and ﬁnally when data was combined prior to analysis
(C). D provides further information on homozygous stretches from combined data
results. Apparently, no larger homozygous regions could be detected which would
be in line with ﬁndings in a consanguineous family. Additionally, results from the
SNP array data diﬀer from those retrieved through exome sequencing as there is no
convincing homozygous region shared by both analyses.
When both information is combined and analysed (ﬁgure 4.4, C, D) the output
reaches higher scores than when analysed separately. Nevertheless, no larger ho-
mozygous blocks could be identiﬁed. Most interestingly, one large region seems to
be identical in all aﬀected individuals. Both the data from the SNP genotyping ar-
ray and the data derived from whole exome sequencing show that all 5 patients are
homozygous and heterozygous for the same polymorphisms in the region between
rs12711538 and rs344689. This might be due to compound heterozygosity for alleles
shared by all patients and could be the disease causing locus. Genotypes for all 5
patients for this region can be found in ﬁgure 4.5 on page 27. A list of all genes
in this region which are expressed in skeletal muscle can be found in table 4.1 on
page 28. Expression data was derived from the Expression Atlas providing data on
tissue expression of all protein coding genes (https://www.ebi.ac.uk/gxa/home).
Among these, Myosin VII B would be a viable candidate gene. Additionally, the
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Figure 4.2.: Parametric linkage analysis of Family 1 (a and b), Family 2 (c
and d), Families 1 to 9 (e and f) and Families 2 to 9 (g and h). a, c, e and g
show linkage analysis for a dominant model and b, d, f and h for a recessive
model of chromosome 2. The location on each chromosome in Centimorgan
(cM) is displayed on the x-axis and the LOD score on the y-axis. The top
grey line in each ﬁeld marks a LOD-score of 3, the purple line marks a LOD
score of 0 and the lower grey bar of -2.
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Figure 4.3.: Parametric linkage analysis of Family 1 (a and b), Family 2 (c
and d), Families 1 to 9 (e and f) and Families 2 to 9 (g and h). a, c, e and g
show linkage analysis for a dominant model and b, d, f and h for a recessive
model of chromosome 10. The location on each chromosome in Centimorgan
(cM) is displayed on the x-axis and the LOD score on the y-axis. The top
grey line in each ﬁeld marks a LOD-score of 3, the purple line marks a LOD
score of 0 and the lower grey bar of -2.
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Figure 4.4.: Homosygosity mapping of individuals from family 2 performed with Ho-
mozygosityMapper. A, B and C show the genome-wide homozygosity scores. A is
based on the SNP genotyping array of individuals II/1, II/2, II/3, II/4 and II/5, whereas
B displays the results based on the exome sequencing data from patients II/2, II/3 and
II/5. C shows the results, when both data is combined. Scores are shown as bars. Red
coloured bars indicate the most promising genomic regions. Note, that grey lines do
not show absolute score values but display the relation to the highest score, which is
plotted to the top grey line. These regions are further speciﬁed in D for the combined
analysis data from the SNP genotyping array and exome sequencing.
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RNA polymerase POLR2D can be found among these which is striking, because the
gene POLR3A is located inside the disease locus for the dominant Family 1.
Figure 4.5.: Genotypes for Individuals II/1, II/2, II/3, II/4 and II/5 from rs12711539
and rs344689 (chromosome 2: 121.837.519 - 140.100.106). This ﬁgure displays the single
genotypes of all samples. Each marker position is depicted as a coloured box. Blue codes
for heterozygosity, grey for unknown and red for homozygosity of a certain genotype
where longer homozygous stretches are drawn in a darker shade of red than single
homozygous markers. The black rectangular surrounds the region from rs12711539 to
rs344689 which is heterozygous and shared by all family members. This implies that
OPDM might be caused by compound heterozygous mutations in this region.
4.4. Exome Sequencing
4.4.1. OPDM I and II
4.4.1.1. Workﬂow
After mapping the disease locus in Family 1 to a region around Chromosome 10:
80,000,000bp, whole exome sequencing of aﬀected individuals I/5 (OPDM1) and
I/10 (OPDM2) was carried out by MWG Euroﬁns. The data was downloaded,
aligned and variants were called and ﬁltered as previously described in chapter 3.4.5
on page 19. Table 4.2 on page 29 describes the applied ﬁltering steps and the number
of remaining variants afterwards. Among the 66,130 variants found in I/5 and the
60,478 in I/10, 24 changes were detected that were rare (allele frequency <1% in
the EVS and 1000genomes project), on target (exonic or splice site), heterozygous,
protein altering, not in duplicated regions and shared by both patients. Duplicated
regions were excluded because variants found here are most likely false positive
calls due to misalignment. Among these, 18 variants were found in genes that are
expressed in skeletal muscle (information taken from https://www.ebi.ac.uk/gxa/
home).
4.4.1.2. Variants detected
Table 4.3 on page 30 summarises 18 variants left after intersection and ﬁltering of
variants from WES of individuals I/5 and I/10 found in genes expressed in skeletal
muscle. Interestingly, most of them do have a dbSNP ID, meaning that they have
already been reported as common polymorphisms. Nevertheless, they are very rare
with most changes not being listed in EVS or the 1000genomes. Additionally, the
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genesymbol description startpos
GLI2 GLI family zinc ﬁnger 2 121493441
TFCP2L1 transcription factor CP2-like 1 121974163
CLASP1 cytoplasmic linker associated protein 1 122095352
TSN translin 122513121
GYPC glycophorin C (Gerbich blood group) 127413426
BIN1 bridging integrator 1 127805599
ERCC3 excision repair cross-complementation group 3 128014866
MAP3K2 mitogen-activated protein kinase kinase kinase 2 128056245
PROC
protein C (inactivator of coagulation factors
Va and VIIIa)
128175996
MYO7B myosin VIIB 128293378
LIMS2 LIM and senescent cell antigen-like domains 2 128395996
GPR17 G protein-coupled receptor 17 128403439
WDR33 WD repeat domain 33 128461808
POLR2D polymerase (RNA) II (DNA directed) polypeptide D 128603840
SAP130 Sin3A-associated protein, 130kDa 128698791
UGGT1 UDP-glucose glycoprotein glucosyltransferase 1 128848754
HS6ST1 heparan sulfate 6-O-sulfotransferase 1 129023054
RAB6C RAB6C, member RAS oncogene family 130737235
SMPD4
sphingomyelin phosphodiesterase 4, neutral
membrane (neutral sphingomyelinase-3)
130908965
MZT2B mitotic spindle organizing protein 2B 130939248
IMP4 IMP4, U3 small nucleolar ribonucleoprotein 131100470
PTPN18
protein tyrosine phosphatase, non-receptor type 18
(brain-derived)
131113580
ARHGEF4 Rho guanine nucleotide exchange factor (GEF) 4 131594489
FAM168B family with sequence similarity 168, member B 131805449
PLEKHB2
pleckstrin homology domain containing, family B
(evectins) member 2
131862420
WTH3DI RAB6C-like 132118065
MZT2A mitotic spindle organizing protein 2A 132227298
TUBA3D tubulin, alpha 3d 132233580
C2orf27A chromosome 2 open reading frame 27A 132479973
C2orf27B chromosome 2 open reading frame 27B 132552534
GPR39 G protein-coupled receptor 39 133174147
LYPD1 LY6/PLAUR domain containing 1 133402337
MGAT5
mannosyl (alpha-1,6-)-glycoprotein beta-1,6-
N-acetyl-glucosaminyltransferase
134877502
CCNT2 cyclin T2 135676363
MAP3K19 mitogen-activated protein kinase kinase kinase 19 135722076
RAB3GAP1 RAB3 GTPase activating protein subunit 1 (catalytic) 135809835
R3HDM1 R3H domain containing 1 136289036
UBXN4 UBX domain protein 4 136499189
LCT lactase 136545415
MCM6 minichromosome maintenance complex component 6 136597196
DARS aspartyl-tRNA synthetase 136664252
CXCR4 chemokine (C-X-C motif) receptor 4 136871919
HNMT histamine N-methyltransferase 138721808
Table 4.1.: List of genes in possible disease locus on chromosome 2 which are expressed
in skeletal muscle and their genomic position on chromosome 2.
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changes in CEP152 and ELANE are predicted to be benign by the program Muta-
tionTaster making it less likely that one of them is causative for OPDM in patients
I/5 and I/10.
Filtering step Number of variants
OPDM1 OPDM2
1. All detected variants 66,130 60,478
2. ...ﬁltered for exonic and
splice site variants
10,266 10,813
3. ...ﬁltered by the pattern
of inheritance
(autosomal, heterozygous)
6,384 6,622
4. ...ﬁltered for a frequency
of <1% in 1000genome and EVS
1,269 1,173
5. ...ﬁltered excluding
synonymous variants
915 848
6. ...ﬁltered excluding variants
in duplicated regions
761 719
7. Variants shared
by both patients
24
8. Variants expressed in skeletal
muscle (EMBL-EBi-GXA)
18
Table 4.2.: Filtering pipeline applied to whole-exome sequencing data from individuals
OPDM1 and OPDM2. Coding exons and splice sites were deﬁned based on the NCBI
annotation.
4.4.1.3. Salient Variants
4.4.1.3.1. MYPN c.3605T>A, p.(V1202E) Among the detected 18 variants,
especially the change c.3605T>A p.(V1202E) in the gene MYPN (NM_032578.3)
seems to be striking. This position is highly conserved in other species and the
change replaces valine by glutamate, meaning the substitution of a hydrophobic for
a positively charged amino acid. This variant is not listed in the EVS, 1000genomes
and dbSNP and is predicted to be disease causing by the program MutationTaster.
The protein myopalladin is a 147kDa muscle scleroprotein which is located in the
I- and Z-discs as well as in the nucleus of cardiac and skeletal muscle cells. It
interacts with alpha-actinin as well as nebulin in skeletal muscle and nebulette in
cardiac muscle with central and C-terminal domains [65]. These complexes tether
actin and titin to the Z-disc. The cardiac ankyrin repeat protein (CARP) is bound
by the N-terminus and is considered to be responsible for the control of muscle
gene expression [66]. Mutation in MYPN are also described to be causative for
hypertrophic, dilatative and/or restrictive cardiomyopathy [67].
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Table 4.3.: List of variants shared by I/5 and I/10 after ﬁltering steps. Column 1
shows chromosome number, column 2 the exact position in base-pairs, column 3 the
gene symbol, column 4 the exact variant description, column 5 the genetic mechanism.
If listed on the EVS server, the allele frequency is provided in column 6 followed by
dbSNP ID in column 7 if available. Columns 8 and 9 display pathogenicity prediction
by the program MutationTaster.
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This change is also in close proximity to the high linkage region (see chapter 4.2
on page 21). It is for these reasons that it was considered the most likely candidate
to be causative for OPDM in Family 1 and further analysis was initiated.
First, exon 18 of MYPN was ampliﬁed by PCR (primer sequences can be found
in the addendum A.1 on page 93) and the c.3605T>A variant was conﬁrmed by
Sanger sequencing in both patients I/5 and I/10 (see ﬁgure 4.7 A on page 32 for
the sequence of patient I/5)
Subsequently, segregation of theMYPN c.3605T>A in all individuals where DNA
was available was tested using the restriction endonuclease DdeI. Results can be
found in ﬁgure 4.6 on page 32. Patient I/5 was used as a positive control and a
healthy individual as a negative control as presence and absence of the change were
previously conﬁrmed by Sanger sequencing. The PCR product has a length of 259bp
and DdeI cleaves oﬀ 50bp in all individuals as the recognition motive 5'-CTNAG-
3' is present once in wildtype PCR products and twice in those with the MYPN
c.3605T>A change. The variant is present, when the remaining 209bp fragment is
further digested into a 116bp and a 93bp fragment. All these can be visualised by
gel electrophoresis. The presence of the MYPN c.3605T>A could be excluded in
all unaﬀected individuals and conﬁrmed in all aﬀected individuals except patient
I/15. The referring clinicians were consulted again and asked to state how certain
the aﬀection status could be determined as the patient had been assessed at only
15 years of age and had only presented with minimal ptosis [5]. Eventually it was
decided to exclude this patient from further studies as the aﬀection status could not
be ascertained beyond doubt.
At a later point in the study, DNA from patient I/13 was sent back from Dres-
den where microsatellite length analysis had been carried out. PCR and Sanger
sequencing of MYPN exon 18 was done and the absence of the MYPN c.3605T>A
could be conﬁrmed in this aﬀected individual as shown in ﬁgure 4.7 on page 32.
As this patient is most certainly aﬀected, presenting with ptosis, ophthalmopare-
sis, swallowing diﬃculties, facial atrophy and limb-girdle weakness [5], the MYPN
c.3605T>A does not segregate with the disease in Family 1.
Before DNA from patient I/13 was available for segregation analysis, the MYPN
c.3605T>A variant was further evaluated by estimating the frequency in ethnically
matched control samples. Therefore, MYPN exon 18 was ampliﬁed by PCR in
74 individuals from Turkey and frequency was estimated by restriction fragment
length polymorphism analysis of PCR products with the restriction endonuclease
DdeI. Apparently, none of the control individuals harboured the c.3605T>A change,
showing that most likely it doesn't constitute a common polymorphism in Turkey.
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Figure 4.6.: Gel electrophoresis for segregation of the MYPN c.3605T>A change. The
MYPN ex18 PCR products for members of Family 1 (I/2, I/16, I/11, I/12, I/8, I/9,
I/15, I/21, I/14) were completely digested with DdeI and the products were analyzed
by 2% agarose gel electrophoresis. Lane M indicates DNA marker, 100bp DNA ladder.
pos and neg lanes were loaded with DNA with conﬁrmed presence or absence of the
MYPN change. + indicates cleavage of DNA by DdeI.
Figure 4.7.: Sanger sequencing of MYPN exon 18 of individuals I/5 (A)and I/13 (B).
Presence of the MYPN c.3605T>A could be conﬁrmed in I/5 and excluded in I/13.
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Next, all exons of MYPN were sequenced in one patient each from all other
Turkish Families 2,3,4,5,6,7 and 8 (published by Durmus et al. in 2001 [5]) as well
as in patients from Finland (FIN/1), France (FRA/1) and Nottingham, UK (NOT).
Primer sequences can be found in the addendum A.1 on page 93. All changes
detected had a minor allele frequency of at least 1% and could therefore be excluded
as possible causes for OPDM in these patients.
4.4.1.3.2. POLR3A c.2551A>G, p.(T851A) A second variant, detected by
whole exome sequencing of patients I/5 and I/10, is the missense mutation POLR3A
(NM_007055.3) c.2551A>G; p.(T851A). The encoded protein of POLR3A is a sub-
unit of the RNA polymerase III, synthesizing small RNAs [68]. It can also recognise
foreign DNA and initiating a consecutive immune response. Mutations in this gene
are reported to cause recessive hypomyelinating leukodystrophy [69]. This vari-
ant substitutes a highly conserved amino acid - even conserved in C.elegans and
Drosophila - and replaces the polar threonine with the hydrophobic alanine, most
likely disrupting the protein structure. It is also predicted to create a new splice
donor site at the genomic position g.29,499. Accordingly, MutationTaster predicts
a disease causing eﬀect. It is also not listed in dbSNP, EVS and 1000genomes.
Presence of the POLR3A c.2551A>G variant was conﬁrmed in patients I/5 and
I/10 by Sanger sequencing (data not shown). Single patients from all other Turkish
families were analysed for the presence of this variant by Sanger sequencing. Ap-
parently, aﬀected individuals from Families 1, 4, 6 and 8 were also carriers of the
c.2551A>G variant.
To further analyse the variant, segregation analysis was done by sequencing of
POLR3A exon 19 in aﬀected and unaﬀected Family 1 members. PCR products
from individuals I/2, I/6, I/8, I/9, I/11, I/12, I/14, I/15, I/16, I/17, I/18 and
I/21 were sequenced. Apparently, the variant segregates well with the disease in
all individuals but I/15 and I/6. These two belong to the younger generation and
according to Durmus et al. 2011 [5], do not have any weaknesses, only minimal
ptosis. The age of onset as well as the initial symptom could not be determined
in I/6. Therefore, the clinical data was not strong enough to exclude the POLR3A
c.2551A>G variant from further analyses. Hence, one aﬀected family member from
all Turkish families has been screened for the POLR3A c.2551A>G variant using
Sanger sequencing with the result that it was present in individuals IV/3, VI/2 and
VIII/2. Segregation of the variant with the disease in families 4, 6 and 8 as well as
the presence in one sporadic patient from Nottingham, UK, France and Canada each
was tested using the restriction endonuclease BsrDI as described in chapter 3.3.4 on
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page 16. BsrDI cleaves the 236bp PCR fragment when the POLR3A c.2551A>G
is present producing a 152bp and a 84bp fragment. There is no recognition site for
the restriction endonuclease in the wildtype PCR product. Results can be found
in ﬁgure 4.8 on page 34. Apparently, the change segregates in all families with the
disease, given that individual IV/1 is indeed unaﬀected. The POLR3A c.2551A>G
variant could not be detected in any of the non-Turkish patients from Nottingham,
UK, Finland and France.
Figure 4.8.: Gel electrophoresis for segregation of the POLR3A c.2551A>G change.
The POLR3A exon 19 PCR products for family 4, 6 and 8 Family members as well as
sporadic patients from Nottingham (NOT), France (FRA) and Finland (FIN), named
in the top row, were completely digested with BsrDI and the products were analyzed
by 2% agarose gel electrophoresis. Lane M indicates the 100bp DNA Ladder. neg
lanes were loaded with DNA with conﬁrmed absence of the c.2551A>G change.
Even though the POLR3A c.2551A>G variant did not perfectly segregate in Fam-
ily 1, the frequency of this change was determined in 58 Turkish control samples.
PCR Products of POLR3A exon 19 were digested with the restriction endonuclease
BsrDI and evaluated by gel electrophoresis as described before. Apparently, the
change was present in 22 out of 58 individuals resulting in a minor allele frequency
of more than 37%. Therefore, the POLR3A c.2551A>G could be excluded as being
causative for OPDM. However, the presence of this polymorphism in families with
a dominant pattern of inheritance implies, that these families share a disease allele
including the c.2551A>G variant.
4.4.2. Exome Sequencing of Individuals OPDM III-VIII
4.4.2.1. Exome Sequencing Results OPDM III-V
As exome sequencing of individuals I/5 and I/10 did not reveal any likely candidate
genes, the study was extended and whole exome sequencing was carried out on 5
more patients. Three siblings from Family 2 (II/2, II/3 and II/5 called OPDM3,
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OPDM4 and OPDM5 respectively) as well as sporadic patients from Nottingham,
UK (OPDM6), from Finland (OPDM7) and from Canada (OPDM8) were chosen
and DNA was sent to Otogenetics, Atlanta, US, where the exome enrichment was
done with the Agilent V4 kit and sequencing done on a Illumina HiSeq 2000. Bioin-
formatic analysis was done as previously described in chapter 3.4.5.2 on page 19.
Additionally, an in-house frequency database was used to ﬁlter out false positive
calls. This database consists of all exome sequencing data sets from the Institute
of Genetic Medicine in Newcastle-upon-Tyne, UK, and provides a minor allele fre-
quency for every detected variant.
Table 4.4 summarises ﬁltering steps of individuals OPDM3, OPDM4 and OPDM5
and the number of variants left after each of them.
Filtering step Number of variants
OPDM3 OPDM4 OPDM5
1. All detected variants 79,915 77,898 77,877
2. . . . ﬁltered for exonic and
splice site variants
18,250 16,924 17,565
3. . . . ﬁltered by the pattern of inheritance
(homozygous/comp. het.)
7,028 6,201 6,561
4. . . . ﬁltered for a frequency of <1% in
1000genome and EVS
197 185 178
5. . . . ﬁltered excluding
synonymous variants
187 181 167
6. . . . ﬁltered excluding variants
in duplicated regions
180 177 163
7. Variants shared
by both patients
104
8. Variants expressed in skeletal
muscle (EMBL-EBi-GXA)
84
9. Variants with an in-house
frequency of <2%
10
Table 4.4.: Filtering pipeline applied to whole-exome sequencing data from individuals
OPDM3, OPDM4 and OPDM5. Coding exons and splice sites were deﬁned based on
the NCBI annotation.
After all variants of individuals OPDM3, OPDM4 and OPDM5 are ﬁltered and
intersected 84 genetic changes remain. Among these 84, 78 are listed in dbSNP. How-
ever, no single change is listed in the EVS and the 1000genome database. When
the in-house minor allele frequency of these genetic changes is determined, it turns
out, that almost all missense variants are very commonly detected in whole exome
sequencing data, thus most likely being false positive calls speciﬁc to the bioinfor-
matical pipeline. When all variants with an in-house frequency greater than 2% are
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ﬁltered out, no single homozygous variant remains in the list and only 10 changes
could be identiﬁed, where two or more can be found in one gene, making compound
heterozygosity possible. These variants can be found in table 4.5 on page 37.
As it is very likely that a compound heterozygous mutation on Chromosome 2 is
causing OPDM in Family 2, genes with two or more heterozygous changes within the
heterozygous region described in chapter 4.3 on page 23 have been identiﬁed. This
region expands from rs12711538 to rs344689 (121,747,406 - 140,100,106bp according
to the hg19 assembly) on Chromosome 2. No single variant could be detected within
this region that is shared or not covered by all three siblings.
Accordingly, special focus was put on the high linkage region on Chromosome 10.
No rare, protein altering changes could be detected between chr10: 49,968,432 and
93,220,242 in any of the three siblings that are shared among them.
4.4.2.2. Exome Sequencing Results OPDM VI
Table 4.6 summarises ﬁltering steps of individual OPDM6 from Nottingham, UK
(patient was assessed and DNA provided by Dr Paul Maddison) and the number of
variants left after each of them.
As the pattern of inheritance cannot be determined in sporadic patients, variants
were ﬁltered for both a dominant and a recessive model. Special focus was put on
variants in the high linkage regions on Chromosome 2 and 10. The only detected
variants near the high linkage locus are a heterozygous AGAP5 (NM_001144000.1)
c.673A>G, p.(M225V) change at the chromosomic position 75,435,676 and a het-
erozygous PIK3AP1 (NM_152309.2) c.775G>A; p.(V259I) at the chromosomic po-
sition 98,411,346. AGAP5 is an ankyrin repeat and GTPase domain and PIK3AP1
a phosphoinositide-3-kinase adaptor protein. Mutations in both genes are very likely
not causing damage to skeletal muscle tissue. On Chromosome 2 two variants could
be detected in NEB (NM_001164507.1), coding for nebulin, a giant protein compo-
nent of the cytoskeletal matrix that coexists with the thick and thin ﬁlaments within
the sarcomeres of skeletal muscle [70]. Mutations in this gene are associated with
recessive nemaline myopathy [71]. These heterozygous changes are c.21044C>G,
p.(S7015C) and c.22122C>G, p.(D7374E). However, none of them are listed in the
Leiden Open Variation Database (LOVD), a database that lists all published dis-
ease causing variants in genes known to cause neuromuscular disorders (http://
www.dmd.nl). Additionally, the c.15941C>G variant is listed in ClinVar, a database
that summarises reports of the relationships among human variations and pheno-
types, and is labelled `likely benign' (http://www.ncbi.nlm.nih.gov/clinvar).
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Table 4.5.: List of possible compound heterozygous variants shared by OPDM3,
OPDM4 and OPDM5. Additionally, genotypes for individuals OPDM6, OPD7 and
OPDM8 for these changes are provided.`R' stands for reference allele and `V' for variant,
meaning that `R/R' implies the presence of two reference alleles, `R/V' heterozygosity
and `V/V' homozygosity for the alternative allele. Coding positions refer to the fol-
lowing transcript variants: NM_002457.3 for MUC2, NM_001164425.1 for MBD3L3,
NM_032447.3 for FBN3, NM_133378.4 for the TTN variants
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Filtering Step Number of variants
1. All detected variants 76,103
2. . . . ﬁltered for exonic and splice site variants 16,769
3. . . . ﬁltered for a frequency of less than 2% in
1000genomes and ExomeVariantServer
1,569
4. . . . ﬁltered excluding synonymous variants 1,203
5. . . . ﬁltered excluding variants in duplicated regions 1,099
6. . . . ﬁltered excluding variants with an
in-house frequency of less than 2%
676
7. variants for a dominant model 509
8. variants for a recessive model 141
Table 4.6.: Filtering pipeline applied to whole-exome sequencing data from individual
OPDM6. Coding exons and splice sites were deﬁned based on the NCBI annotation.
The dominant model includes all heterozygous variants with a frequency of less than 1%
in EVS, 1000genomes and in-house minor allele frequency (MAF) . The recessive model
comprises all variants with a frequency of less than 2% in the databases mentioned above
that are either homozygous or where two or more changes were detected in one gene.
Also, a total number of 4 heterozygous genetic changes in the gene TTN could
be detected. This gene encodes a large structural protein of striated muscle. It
expands from the Z-disc of the sarcomere with its N-terminus to the M-line with
its C-terminus. It also possesses binding sites for other muscle associated genes and
acts as a template for the contractile machinery of muscle ﬁbres [70]. As it is one
of the largest genes in the human genome great variability exists, especially in the
Z-disk-, the M-line- and the I-band regions. Mutations in titin are associated with
a number of pathologies such as dilated cardiomyopathy, autosomal dominant tibial
muscular dystrophy as well as autosomal recessive limb girdle muscular dystrophy
2J [72], [73]. These variants in the TTN -gene (NM_003319.4) are: c.41935C>T,
p.(P13979S), c.18052C>T, p.(R6018W), c.11491A>T, p.(I3831F) and c.1492G>A,
p.(V498I). However, none of them is listed in the LOVD database but the ﬁrst two
and the last one are listed as `benign' or `likely benign' in ClinVar.
One interesting variant could be detected in the RYR1 gene (NM_000540.2), a
heterozygous c.8382C>G, p.(Y2794X) nonsense mutation. This variant is not listed
in the EVS and the 1000genome database and is most certainly disrupting the pro-
tein structure as a premature stop-codon leads to the loss of almost half the protein
chain. This large gene, counting 106 exons, located at 19q13.2, encodes the protein
Ryanodin Receptor 1, functioning as a calcium release channel in the sarcoplasmic
reticulum in skeletal muscle. Its function is also to connect the sarcoplasmic retic-
ulum to the transverse tubule. Mutations in this gene reportedly cause autosomal
dominant or recessive central core myopathy, autosomal recessive minicore myopa-
thy with external ophthalmoplegia and malignant hyperthermia susceptibility [74],
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[75],[76],[77]. Hence, it needs to be discussed, if central core myopathy could mimic
an OPDM phenotype and if this variant could be responsible for it.
4.4.2.3. Exome Sequencing Results OPDM VII
Table 4.7 summarises ﬁltering steps of individual OPDM7 from Finland and the
number of variants left after each of them (patient was assessed and DNA provided
by Professor Bjarne Udd).
Filtering Step Number of variants
1. All detected variants 89,346
2. . . . ﬁltered for exonic and splice site variants 16,702
3. . . . ﬁltered for a frequency of less than 2% in
1000genomes and ExomeVariantServer
1642
4. . . . ﬁltered excluding synonymous variants 1,275
5. . . . ﬁltered excluding variants in duplicated regions 1,181
6. . . . ﬁltered excluding variants with an
in-house frequency of less than 2%
715
7. variants for a dominant model 530
8. variants for a recessive model 132
Table 4.7.: Filtering pipeline applied to whole-exome sequencing data from individual
OPDM7. Coding exons and splice sites were deﬁned based on the NCBI annotation.
The dominant model includes all heterozygous variants with a frequency of less than 1%
in EVS, 1000genomes and in-house MAF. The recessive model comprises all variants
with a frequency of less than 2% in the databases mentioned above that are either
homozygous or where two or more changes were detected in one gene.
Variants were analysed on the basis of a recessive and a dominant model as pre-
viously described in chapter 4.4.2.2 on page 36. Special focus was put on the high
linkage regions on Chromosome 2 and 10 as well as on changes in genes which are
associated with neuromuscular disorders. Among the 3 homozygous variants left
after all ﬁltering steps, none were found in the high linkage regions on Chromosome
2 or 10 or otherwise interesting. Two variants in the gene GLI2, encoding a zinc
ﬁnger and transcription factor of Sonic hedgehog signaling could be detected on
Chromosome 2 [78]. Variants in this gene are associated with various phenotypes of
malformation [79]. The identiﬁed heterozygous variants in GLI2 (NM_005270.4)
are: c.4332G>A, p.(M1444I) and c.4333C>T, p.(L1445F). However for a domi-
nant model, two variants could be detected on Chromosome 10 that are located in
the high linkage region. These are POLR3A (NM_007055.3) c.275G>C, p.(C92S)
and NRG3 (NM_001010848.3):c.1951G>A, p.(E651K) at the chromosomic posi-
tions 79,785,423 and 84,745,221 respectively. Both variants cause the substitution
of conserved amino acids and are predicted to be deleterious by various prediction
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tools such as SIFT and MutationTaster. Both changes are listed in the EVS and
the 1000genome database but have a very low frequency. The POLR3A change is
annotated with frequencies of 0,000093 in the EVS and 0,0005 in the 1000genome
database and the NRG3 change with 0,002417 and 0,0023 accordingly. The protein
encoded by POLR3A has been described previously in 4.4.1.3.2 on page 33. NRG3
encodes a ligand for the transmembrane tyrosine kinase ERBB4 which is a member
of the epidermal growth factor receptor family [80]. Neuregulin 3 is thought to in-
ﬂuence neuroblast proliferation, migration and diﬀerentiation through ERBB4 [81].
It is susceptible to be associated with schizoaﬀective disorders and schizophrenia
[82]. Other interesting variants include a heterozygous change in the RYR1 gene
which was described above. This c.785C>T, p.(A262V) change is not listed in the
EVS and has a frequency of 0,0005 according to the 1000genomes database. It is
found in a highly conserved position but mutation prediction tools are inconsistent
with some predicting a deleterious eﬀect (PolyPhen2, PhyloP) whereas other claim
that is most likely benign to the protein structure (MutationTaster, LRT). This is
most likely, because the amino acid substitution replaces a non-polar alanine with
the likewise non-polar valine. The presence of this variant was conﬁrmed by Sanger
sequencing in this patient. Nevertheless, this is the second individual with a variant
in the gene RYR1 and it needs to be discussed, if these patients are aﬀected with
central core myopathy instead of OPDM.
4.4.2.4. Exome Sequencing Results OPDM VIII
Table 4.8 summarises ﬁltering steps of individual OPDM8 from Canada and the
number of variants left after each of them (patient was assessed and DNA provided
by Professor Bernard Brais).
As in OPDM VI and OPDM VII, especially variants within the high linkage re-
gions on Chromosome 2 and Chromosome 10 as well as those within genes associated
with neuromuscular disorders were taken account of. For a recessive model, none
of the three homozygous variants (NDUFS7 c.T617A, p.(L206H) on Chromosome
19, LILRB1 c.893C>A, p.(S298Y) on Chromosome 19 and IFNA10 c.496G>A,
p.(V166I) on Chromosome 9) seem to be likely disease-causing. However, three
variants were detected in the TTN gene on Chromosome 2, namely c.4332G>A,
p.(M1444I), c.12571G>A, p.(V4191M) and c.10366G>A, p.(V3456I). Out of these,
only the c.12571G>A change is listed with a frequency of 0,007965 in the ESP5400
and 0,0046 in the 1000genomes database. None of these variants is listed in the
LOVD database. The ﬁrst variant is a substitution of the non-polar amino acid
methionine with the likewise non-polar isoleucine. Similarly, the non-polar valine is
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Filtering Step Number of variants
1. All detected variants 75,682
2. . . . ﬁltered for exonic and splice site variants 18,011
3. . . . ﬁltered for a frequency of less than 2% in
1000genomes and ExomeVariantServer
1,800
4. . . . ﬁltered excluding synonymous variants 1,345
5. . . . ﬁltered excluding variants in duplicated regions 1,253
6. . . . ﬁltered excluding variants with an
in-house frequency of less than 2%
667
7. variants for a dominant model 516
8. variants for a recessive model 119
Table 4.8.: Filtering pipeline applied to whole-exome sequencing data from individual
OPDM8. Coding exons and splice sites were deﬁned based on the NCBI annotation.
The dominant model includes all heterozygous variants with a frequency of less than 1%
in EVS, 1000genomes and in-house MAF. The recessive model comprises all variants
with a frequency of less than 2% in the databases mentioned above that are either
homozygous or where two or more changes were detected in one gene.
changed to methionine in the second change and valine replaced with isoleucine in
the third. Thus, it is very hard to predict a pathogenic potential for any of these
variants. Close to the locus on Chromosome 10, two heterozygous variants were
detected in the genes PLAU and WAPAL at chromosomic locations 75,675,086 and
88,230,804 respectively. PLAU encodes a urinary plasminogen activator, involved
in thrombolysis and mutations in this gene are associated with Quebec Platelet
Disorder [83]. WAPAL (wings-apart-like homolog from Drosophila) is involved in
the removal of cohesins from the mitotic human chromosomes and therefore act to
protect from segregation errors and aneuploidy [84]. Considering the gene function
as well as the genomic locations, both changes are an improbable cause of OPDM
in this individual.
However, three heterozygous changes in genes, known to be associated with neu-
romuscular disorders, could be detected. The ﬁrst one is a c.1564G>A, p.(G522R)
change in the gene MEGF10. The protein encoded by this gene is involved in cell
motility, proliferation as well as adhesion. It also plays a role in cell phagocytosis
during apoptosis and amyloid-beta uptake in the brain [85]. Mutations in this gene
cause either autosomal recessive early-onset myopathy, areﬂexia, respiratory dis-
tress, and dysphagia (EMARDD) or congenital myopathy with minicores [86], [87].
The c.1564G>A, p.(G522R) variant replaces a non-polar glycine with the positively
charged basic polar amino acid arginine, most likely altering the protein structure.
It has a frequency of 0.002231 in ESP5400 and 0.0009 in the 1000genomes database
and is predicted to be deleterious by all prediction tools.
41
4. Results
The second change is a heterozygous c.655C>T, p.(R219X) nonsense variant in
MYOT, a gene encoding for myotilin, which has been conﬁrmed by Sanger sequenc-
ing. This protein binds several skeletal muscle structural proteins such as F-actin
and alpha-actinin and plays a crucial role in stabilising and anchoring of thin ﬁla-
ments of the sarcomere [88]. Mutations in this gene are associated with a number
of autosomal dominant neuromuscular conditions; namely limb-girdle muscular dys-
trophy, Type 1A [89], myoﬁbrillar myopathy 3 [90] and spheroid body myopathy
[91]. This variant has not been published yet and is not listed in the LOVD. As the
nonsense mutation most certainly aﬀects protein integrity it needs to be discussed,
if this mutation could be the underlying genetic defect for this patient's phenotype.
In addition to the changes mentioned above, a heterozygous c.313C>T, p.(R105C)
variant in the geneMATR3 at the genomic position chr5:138,660,985 in the hg19 as-
sembly was detected. Matrin 3 is a nuclear matrix protein that binds DNA and RNA
[92]. It is known to cause autosomal dominant Amyotrophic Lateral Sclerosis 21, for-
merly called vocal cord and pharyngeal dysfunction with distal myopathy (VCPDM)
[93], [94]. This variant is a substitution of the polar and positively charged amino
acid arginine with the non-polar cysteine and is conclusively most likely altering
the protein structure. However, this variant is located at the exon-intron bound-
ary of intron 13 and exon 14 in only some of the common transcript variants (e.g.
NM_018834.5). It also changes the strength of two splice acceptor sites at positions
g.51556 (wt:0.42/mu:0.56) and g.51547 (wt:0.24/mu:0.36) according to the calcula-
tions of the program MutationTaster as shown in ﬁgure 4.10 on page 43. Other splice
site prediction tools have been used to further validate this in silico analysis, ASSP
(alternative splice site prediction; http://wangcomputing.com/assp/) and Fruitﬂy
(http://www.fruitfly.org/seq_tools/splice.html) [95], [96]. The score for the
alternative splice acceptor site (Exon 14a alt. in ﬁgure 4.10 c) increases from 7.012
to 7.609 according to ASSP. The score for the splice acceptor site, resulting in exon
14a (ﬁgure 4.10 b), decreases from 8.424 to 8.020. Fruitﬂy predicts no change in the
strength for this site (0.89 -> 0.90) but an increase form 0.50 to 0.70 for the cryptic
acceptor site resulting in exon14a alt.
Therefore it needs to be discussed if the frequency of this particular transcript
variant is increased by the altered splice acceptor site strength and, if that is the
case the missense mutation disrupts the protein structure.
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Figure 4.9.: Position of the variant in MATR3 : c.313C>T, p.(R105C). The nine
lines comprise nine diﬀerent UCSC transcript variants. Transcripts in darker blue
accord the consensus coding sequence (https://www.ncbi.nlm.nih.gov/projects/
CCDS/CcdsBrowse.cgi). Note that the variant only aﬀects the protein sequence of
transcript variant NM_018834.5. However, it alters the strengths of splice acceptor
sites and might therefore increase the frequency of NM_018834.5.
Figure 4.10.: Predicted isoforms of MATR3 and the in silico predicted eﬀect of the
c.313C>T variant. a shows the most common and b the 144bp longer alternative
transcript variant where the c.313C>T, p.(R105C) is located in exon 14a. This variant,
however, also creates a cryptic splice acceptor site resulting in a 14bp smaller alternative
exon 14a, displayed in c.
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4.5. Fine mapping the disease locus for Family 1
4.5.1. Fine mapping of the locus on Chromosome 10
Fine mapping of the locus on Chromosome 10 was undertaken by haplotype con-
struction and identiﬁcation of recombinant haplotypes by use of genotyping data for
the 53 markers that span the region of interest. Among these, 18 are microsatellites
and 35 are SNP markers with a frequency greater than 5%. A list of the microsatel-
lite markers can be found in table 3.5 on page 19. As the aﬀection status of the
youngest generation could not be determined with conﬁdence, a total of 9 aﬀected
individuals from generations 3 and 4 were studied and several recombinant haplo-
types identiﬁed. Reconstruction was carried out in a way that ensured that the
largest possible chromosomic region was covered. The most telomeric microsatel-
lite marker, D10S1686, turned out to be uninformative. Therefore, the telomeric
recombination point located at chromosomic position 85,566,388bp had to be deter-
mined based on SNP data to rs1188786, most likely overestimating the size of the
locus (all positions referring to the hg19 assembly). The centromeric recombination
point could be identiﬁed by sequencing a synonymous POLR3A (NM_007055.3)
c.2829C>T change that did not segregate with the disease in all patients and is
therefore determined at chromosomic position 79,750,884bp. The identiﬁed disease
locus consequently spans from position 79,750,884 to 85,566,388 within Chromosome
10. The reconstruction of recombinant haplotypes and the recombination points can
be found in ﬁgure 4.11 on page 46.
4.5.2. Characterization of the locus
Given, that a conserved haplotype could be identiﬁed, the region on Chromosome
10: 79,750,884 - 85,566,388 was further analysed. Figure 4.12 shows a schematic
Chromosome 10 q22.3q23.1 area linked to autosomal dominant OPDM as well as all
genes located in this region. A total number of 44 genes could be found of which
28 are protein-coding. 19 of them are reported to be expressed in skeletal muscle
according to either the in Common Fund's Genotype-Tissue Expression (GTEx)
[93]database (http://www.gtexportal.org/home/) or the Human Protein Atlas
(HPA) (http://www.proteinatlas.org/) [97], [98]. A list of these can be found
in table 4.9 on page 45 and 45.
Gene Expression Expression Gene Function
Symbol in GTEx in HPA
POLR3A X Catalytic component of RNA polymerase III,
which synthesizes small RNAs. Also acts
as a sensor to detect foreign DNA and
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trigger an innate immune response.
RPS24 X Encodes a ribosomal protein that is a
component of the 40S subunit.
Mutations result in Diamond-Blackfan anemia.
PLAC9 X Homo sapiens placenta-speciﬁc 9
ZMIZ1 X Member of the PIAS (protein inhibitor of
activated STAT) family of proteins.
It regulates the activity of various
transcription factors, including the
androgen receptor, Smad3/4, and p53.
It may also play a role in sumoylation.
A translocation between this locus on
Chromosome 10 and the protein tyrosine
kinase ABL1 locus on chromosome 9 has
been associated with acute lymphoblastic
leukemia
DYDC1 X X Member of a family of
proteins that contains a DPY30 domain.
It is involved in acrosome formation
during spermatid development.
PPIF X Member of the peptidyl-prolyl
cis-trans isomerase (PPIase) family.
PPIases catalyse the cis-trans
isomerization of proline imidic peptide bonds
and accelerate the folding of proteins.
Part of the mitochondrial permeability
transition pore in the inner mitochondrial
membrane. Activation of this pore
may be involved in the induction
of apoptotic and necrotic cell death.
ZCCHC24 X X Zinc ﬁnger, contains a CCHC domain
SFTPD X Part of the innate immune response,
protecting the lungs against
inhaled microorganisms and chemicals.
May also be involved in surfactant metabolism
SH2D4B X SH2 domain containing 4B
EIF5AL1 X Eukaryotic translation initiation factor
5A-like 1
TMEM254 X Transmembrane protein 254.
ANXA11 X X Member of the annexin family,
a group of calcium-dependent phospholipid-
binding proteins. It is recognized by
sera from patients with various
autoimmune diseases.
FAM213A X X Involved in redox regulation of the cell.
Acts as an antioxidant. Inhibits TNFSF11-
induced NFKB1 and JUN activation and
osteoclast diﬀerentiation. May aﬀect bone
resorption and help to maintain bone mass.
TSPAN14 X X Tetraspanin 14.
Table 4.9.: List of genes and their function in the reﬁned locus on Chromosome 10:
77,991,127 - 84,563,458. The gene information was extracted from: http://www.ncbi.
nlm.nih.gov/mapview/. Source for gene-expression information is: https://www.ebi.
ac.uk/gxa/experiments/.
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Figure 4.11.: Reconstruction of Family 1 recombinant haplotypes for Chromosome 10:
77,991,127-84,563,458 based on 50 markers. The disease haplotype is shown in black
colour. The youngest generation was not considered as their aﬀection status could not
be determined with conﬁdence. Haplotypes were reconstructed manually to result in
the largest possible shared haplotype.
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Figure 4.12.: Characterisation of the shared haplotype region Chromosome 10:
77,991,127-84,563,458. (A) Chromosomal location of the disease locus indicated by
the red box: Chr10 (q22.3q23.1). (B) Map of all genes found in the locus. (C) Map
containing all protein coding genes inside the locus.
4.6. Chromosome 10 Locus Sanger Sequencing
Since whole exome sequencing did not cover all coding exons of the 44 genes in
the disease locus for Family 1 with a read depth of at least 10, Sanger sequencing
was used to screen all of them for undetected variants. A list of primers used can
be found in the addendum A.1 on page 93. Uncovered exons were ampliﬁed by
PCR and sent to MWG Euroﬁns for Sanger-sequencing. These were found in genes
NRG3, RPS24, ZMIZ1, PPIF, EIF5AL1, C10orf57, PLAC9, ANXA11, SH2D4B,
AK302451, AX747983, ZCCHC24, FAM213A, MAT1A, GHITM, CDHR1, LRIT2,
LRIT1. No single mutation could be detected that is not listed in the dbSNP
database with a frequency greater than 1% apart from a EIF5AL1 c.254A>G,
p.(K85R) variant.
4.6.1. MicroRNAs Within the Disease Locus for Family 1
As the results so far do not show any convincing variants in the coding sequences of
genes within the disease locus for Family 1, the two microRNAs found in this region,
MIR_554 (chr10: 83,467,245-83,467,350) and hsa-miR-3198-3p (chr10: 82,904,458-
82,904,477), were analysed by Sanger sequencing. Primer sequences can be found in
the addendum in A.1 on page 93. No variants that are not listed with a frequency
of less than 1% in dbSNP could be detected in these two microRNAs.
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4.6.2. EIF5AL1 c.254A>G, p.(K85R)
When uncovered exons within the locus were sequenced, a rare missense variant
in the gene EIF5AL1 (NM_001099692.1) was discovered: c.254A>G, p.(K85R).
This change is listed in dbSNP with the ID rs201647668 but was neither found
in the ESP or the 1000genomes databases. It is reported to have a minor allele
frequency of 0.3% according to dbSNP build 146. The amino acid change replaces
the basic polar positively charged lysine with the likewise basic polar positively
charged arginine. Nevertheless, the variant is predicted to be disease causing by
the program MutationTaster. The gene EIF5AL1 encodes the eukaryotic translation
initiation factor 5A-like 1, a homologue of the eukaryotic translation initiation factor
5A. The function of EIF5AL1 is still unknown, EIF5A, however, plays a role in
the elongation phase and, more speciﬁcally, stimulates the production of proteins
containing runs of consecutive proline residues. It is the only known protein where a
lysine residue is post-translationally modiﬁed to hypusine [99]. It is predicted to be
expressed in skeletal muscle by the Illumina body map (https://www.ebi.ac.uk/
gxa/home) but not by the UniGene database, which oﬀers an expression sequence
tag (EST)-based expression proﬁle (http://www.ncbi.nlm.nih.gov/est/). This
variant was detected in patient I/9 and conﬁrmed in patient I/5. Therefore it is most
likely present in all aﬀected individuals, as it is located on the conserved haplotype.
To see if the change segregates in other OPDM families as well, aﬀected individuals
from all other Turkish pedigrees (III/2, IV/3, V/1, VI/1, VII/2, VIII/2) as well as
three patients from France, and two from the United Kingdom were genotyped for
this change. Apparently, the variant could be detected in all of them. 36 Turkish
control samples were screened for the c.254A>G, p.(K85R) variant as well and it
was present in all. Most likely, the primers bind to other homologues of EIF5A with
homology in all bases except for this, where the variant was assumed to be.
4.6.3. Triple Repeat Analysis
As OPMD, which is phenotypically very similar to OPDM, is caused by a triple-
repeat expansion in the gene PABPN1, intronic triple- and hexarepeats within the
disease locus on Chromosome 10 were analysed. Five repeats were found in the
genes NRG3, and one in LOC219347, ZMIZ1, LOC100132987 and TSPAN14 each.
They were ampliﬁed by PCR in individual I/9 followed by Sanger sequencing. PCR
reactions did not work for the TSPAN14 - as well as for the NRG3 repeats 2 and 5.
The ﬁrst triple-repeat in intron 1 of NRG located at chr10: 83,665,964-83,665,990
in the hg19 assembly appears to be homozygous for a total number of eight ATC
repeats (ATC)8. The average length in control individuals is 8.7. However, larger
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repeat expansions and complete deletions cannot be detected by Sanger sequencing.
The third, a CAC-repeat within NRG3, was ampliﬁed, sequenced and analysed
with the program Chromas and the website BLAST. Interestingly, the alignment
maps to a region on Chromosome 11: 70,895,189-70,895,773. The primer pairs were
reevaluated but are speciﬁc to the repeat in intron 2 of NRG3, mispriming can
almost be excluded. A TTA-repeat within the NRG3 gene, located in intron 4
(Chr10: 84,429,004 - 84,429,044) shows an average length of (TTA)13.3 . In patient
I/9 it could be determined as 11 and 13. Additionally, triple-repeats in non-coding
genes within the disease locus were analysed. The length of the intronic TTG-repeat
in LOC100132987 was found to be (TTG)9, while the average length in controls is
11.7. The sequence appeared to be homozygous. The intronic AAT-repeat in the
gene LOC219347 appeared to be heterozygous with lengths of 12 and 15. The
average length is reported being (AAT)14. The intronic TTA-repeat in the gene
ZMIZ1 located at chr10:81,038,152 - 81,038,182 appeared to be homozygous for a
length of 11 triplets whereas the average in controls is 9.7.
4.7. Array-CGH
DNA from patient I/5 was sent to the Medizinisch Genetisches Zentrum, Munich
for comparative genomic hybridization on a microarray (array CGH). Array CGH is
a molecular cytogenic method to study copy number variations [100]. It is employed
to uncover deletions, ampliﬁcations, breakpoints and ploidy abnormalities which
might be causing OPDM as no single mutation could be detected in the coding
regions within the disease locus for Family 1. Unfortunately, the analysis failed due
to bad quality of the DNA sample. As patients live in a very remote area of Turkey,
no new blood samples could be collected for a reanalysis.
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5.1. Is OPDM a genetically heterogeneous disease?
To identify the genetic cause or causes of OPDM mapping by linkage analysis fol-
lowed by reconstruction of recombinant haplotypes was performed and exome se-
quencing was done to detect possible causative variants. However, it is not certain
yet, if OPDM is a homogeneous disease and this needs to be discussed ﬁrst, as
diﬀerent families with diﬀerent genetic background were included in this study.
Studying the literature of all OPDM cases reported so far revealed that there is
some variation in the clinical as well as the histological presentation. For exam-
ple, two patients with autosomal dominant OPDM were also diagnosed with dilated
cardiomyopathy  a ﬁnding not common among other OPDM patients [7]. Some
patients show tubuloﬁlamentous inclusions in the nuclei but some do not in electron
microscopy ultrastructural studies [6]. Most importantly, both autosomal domi-
nant and autosomal recessive inheritance reportedly imply genetic heterogeneity [5].
Nevertheless, OPMD, witch is phenotypically a very similar neuromuscular disorder,
presents with both dominant and recessive inheritance, depending on the length of
the GCG repeat expansion in the gene PABPN1 and a similar mechanism could be
responsible in OPDM.
Therefore, linkage analysis was performed separately for the dominant Family 1
and the recessive Family 2 and results show that there is a clear dominant disease
locus on chromosome 10. The LOD-score for this region, however, is around 0
for family 2 for both a dominant and a recessive model. The genotyping array
and microsatellite analysis revealed that OPDM could be mapped to a locus on
chromosome 2 for Family 2, for which all patients should be compound heterozygous.
Yet, linkage analysis of Family 1 revealed a negative LOD-score for this region. In
summary, this study shows that OPDM is a genetically heterogeneous disease and all
families should be analysed with special focus on the loci identiﬁed on chromosome
2 and 10.
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5.2. Possible Genetic Causes for OPDM in Family 1
5.2.1. Intronic and UTR Repeat expansions
As exome sequencing of two individuals from Family 1 did not result in any ob-
vious candidate genes, it needs to be discussed, which genetic variants could be
causative for OPDM but missed by this technology. The most plausible would be
repeat expansions either in coding or non-coding regions due to the similarity to
other neuromuscular disorders, especially OPMD. Repeat expansions can either be
pathogenic on RNA or protein level. In OPMD, oligomerisation of polyalanine ex-
panded PABPN1 results in nuclear protein aggregation and causes cell death [101].
Depending on the number of expanded GCG-repeats, OPMD is inherited with a
autosomal dominant or recessive trait which also conforms to the fact that most
families aﬀected by OPDM stem from a small region in Turkey and show both dom-
inant and recessive inheritance. The idea of whole exome sequencing is to detect
all protein altering mutations and therefore only the coding regions are enriched.
Repeat expansions in the untranslated regions (UTRs) of genes and the introns are
commonly missed if they are not close to the exons. Additionally, larger expansions
cannot be identiﬁed by the methods used in this study (Illumina HiSeq 2000) be-
cause the additionally inserted bases cause too many mismatches in comparison to
the reference genome. For a more detailed description see chapter 5.7.1 on page 67.
5.2.2. Transcription-Reducing Variants
A second conceivable mechanism to explain which genetic defect could lead to
OPDM is mutations that reduce transcription of a certain gene. These are com-
monly found in the promoter region e.g. in the RNA-polymerase binding site or
regulatory elements. There are not many reported cases with this underlying ge-
netic mechanism because ﬁrstly, they are rare and secondly diﬃcult to identify as
they are not enriched by whole exome sequencing. One example would be a study
of patients with limb-girdle muscular dystrophy type 2O (OMIM #613157) where a
9bp deletion was detected in the promoter region of POMGNT1 resulting in reduced
expression [102]. As the promoter regions are commonly not covered by WES this
could be the genetic aberration leading to OPDM. A second mechanism how tran-
scription could be reduced are mutations in the UTRs. Even though they do not
change the amino acid structure of the protein, they are transcribed and might aﬀect
post-transcriptional regulation. There is a number of processes involved that control
mRNA half-life and conclusively protein translation. First, there is capping of the 5-
prime end of the mRNA to protect it from 5' exonuclease as well as polyadenylation
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of the 3-prime end which adds adenine bases to the 3' end to buﬀer the eﬀects of
the 3' exonuclease. Long poly(A) tails therefore correlate with a long half-life [103].
Additionally, a long poly(A) tail can increase translation by binding of poly(A)
binding proteins (PABP) that initiate the translation through interaction with the
eukaryotic initiation factors EIF4E and EIF4G [104]. Second, a process called RNA
editing can alter the sequence of mRNA molecules by deamination of adenosine to
inosine bases. This reaction is catalysed by `Adenosine Deaminase Acting on RNA'
(ADAR) enzymes and can alter the splicing and translation machineries, the double-
stranded RNA structures and the binding aﬃnity between RNA and RNA-binding
proteins with unpredictable eﬀects [105]. And third, microRNA mediated regulation
controls the expression of about 60% of all protein coding genes [106]. These genes'
mRNAs have conserved binding sites, mostly found in the 3' UTR, for microRNAs
that reduce expression. Conclusively, mutations in this region can either create a
microRNA binding site or lose one and therefore alter the expression of a gene. Re-
cently, a study has demonstrated that mutations in the 3' UTR of GFPT1 creates
a new binding site for miR-206* resulting in repression of translation and causing
congenital myasthenic syndrome in the aﬀected individuals [107]. These genetic
mechanisms should be considered possible causes for OPDM.
5.2.3. Copy Number Variation
A third group of genetic aberration that can cause disease in mammals is copy
number variation (CNVs). This is a phenomenon where sections of the genome are
repeated  usually duplicated, seldom triplicated or quadruplicated  or deleted.
There are a number of disease phenotypes associated with CNVs most of which are
congenital malformations and mental retardations. Some are caused by loss of gene
function due to under- or overexpression such as deletions in TBX1 causing Velocar-
diofacial Syndrome (OMIM #192430) [108], or PMP22 resulting in Charcot-Marie-
Tooth disease type 1A (OMIM #118220) [109]. Others are caused by overexpression
and protein aggregation such as duplications of the APP gene in Alzheimers disease
or SNCA in Parkinsons disease [110], [111], [112]. Quite recently, Ankala and col-
leagues have studied 41 genes by next-generation sequencing and array CGH and
discovered a rate of 5 CNV out of 70 patients presenting with congenital muscular
dystrophies (CMD) and 8 CNV out of 193 patients presenting with limb-girdle mus-
cular dystrophies (LGMD) . Conclusively, it seems to be a common genetic mecha-
nism in neuromuscular disorders [113]. However, detection of copy number variation
is challenging from whole-exome sequencing data, as the coverage is much more vari-
able compared to whole-genome sequencing [114] and computational algorithms are
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still being improved to increase speciﬁcity and sensitivity of CNV prediction from
NGS-data [115].
5.2.4. Candidate Genes in the Locus on chromosome 10
As ﬁne-mapping deﬁned a clear disease locus for Family 1 by reconstruction of
recombinant haplotypes (4.5 on page 44) and no missense or nonsense variants were
identiﬁed in this region, it was discussed which other genetic mechanisms could
be underlying OPDM in these patients. Thus, genes within the locus have to be
evaluated for a candidate gene approach.
One of the genes, located within the disease locus on chromosome 10 is NRG3.
Neuregulin 3 is a ligand for the Erbb4 transmembrane tyrosine kinase receptor and
can signal in an autocrine, paracrine and juxtacrine fashion [116]. Erbb4 activa-
tion mediates cell migration, control of cell proliferation, cell stratiﬁcation, and cell
adhesion in developmental as well as pathogenic processes in the nervous system,
heart, kidney, and mammary gland [116], [117]. It has been shown to be involved in
embryonic mammary gland development [118] but little is known about its function
in the developing brain, where it is highly expressed, and in skeletal muscle tissue.
Common genetic variation in NRG3 is thought to increase the risk of schizophrenia
[82].This gene, even though not expressed in skeletal muscle is particularly interest-
ing because its introns contain a large number of repeats, which might be causing
OPDM when expanded. A recent study has shown that a microsatellite repeat ex-
pansion within intron 7 in the NRG3 gene correlates with reduced levels of NRG3
expression. However, the phenotypical correlation was impaired mammary gland
development in mice, reducing the possibility of an association with a muscle pheno-
type [119]. Nevertheless, repeats within this gene should be screened for expansions
in further studies to identify the mutation causing OPDM in this family.
POLR3A is a subunit of the RNA polymerase III which transcribes genes encoding
ribosomal 5S RNA, tRNAs, U6 small nuclear RNA, mitochondrial RNA-processing
RNA, H1 RNA, Y RNAs, and 7SK RNA [68]. 5S RNA is imported into mitochon-
dria but, more importantly, is also an essential component of the large ribosomal
60S subunit and reduced or increased expression might aﬀect protein biosynthesis
resulting in a muscle phenotype with rimmed vacuoles in histological studies repre-
senting protein depositions [120]. The U6 small nuclear RNA is involved in splice
site detection and conclusively, impaired or excessive transcription could result in
a huge amount of alternatively spliced mRNA and therefore cause disease [121].
Mutations in the gene POLR3A have been associated with recessive hypomyelinat-
ing leukodystrophy (MIM #607694) [69] but it cannot be excluded that an OPDM
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phenotype is a variant speciﬁc phenotype resulting from mutations in the POLR3A
gene. Conclusively, further studies such as whole-genome sequencing should be done
to detect or exclude genetic variation within the POLR3A gene.
A third interesting gene, found within the detected disease locus is PPIF, encod-
ing Cyclophilin D, a mitochondrial peptidyl-prolyl cis/trans isomerase. Cyclophilins
catalyse the cis to trans isomerisation of certain proline imidic peptide bonds but
Cyclophilin D is also known to be an activator of the mitochondrial permeability
transition pore (MPTP) [122], [123]. Under certain conditions like oxidative stress
or calcium overload, the pore opens and allows free passage of smaller molecules
over the mitochondrial membranes resulting in ATP depletion by uncoupling of ox-
idative phosphorylation and conclusively necrotic cell death. PPIF deﬁcient mice
(PPIF-/-) showed protection against reperfusion injury after ischemia of heart and
brain tissue due to the reduced activity of the MPTP, whereas overexpression of
PPIF in cardiac tissue lead to mitochondrial swelling and spontaneous cell death
[124]. Knockout of PPIF in a mouse model for sarcoglycanopathies (SGCD-/-),
a limb-girdle muscular dystrophy showed markedly less dystrophic disease in both
skeletal muscle and cardiac muscle compared to a single knockout of SGCD [125].
Conclusively, mutations leading to a gain of function of PPIF could result in mito-
chondrial swelling and necrotic cell death of muscle ﬁbres and might be causative
for OPDM.
5.3. Possible Genetic Causes for OPDM in Family 2
5.3.1. Recessive or Dominant Trait?
When discussing the possible underlying genetic defect responsible for OPDM in
Family 2 it ﬁrst needs to be deliberated whether the disease in this family follows a
dominant or recessive inheritance pattern. At ﬁrst glance, this is easy to answer - as
the parents are reported to be consanguineous and none of them are aﬀected, it is
recessive. However, the chances of being homozygous for the mutation is 25% and
one would not expect 5/6 of the descendants to be aﬀected by the disease. Addi-
tionally, one would assume that the patients in this family would be homozygous in
the regions with a high LOD-score in the linkage analysis. Nonetheless, haplotyping
for chromosome 2, as well as homozygosity mapping revealed, that the patients all
inherited the same allele from their mother but a diﬀerent one from their father
that is likewise shared by all aﬀected siblings (see ﬁgure 4.5 on page 27 and ﬁg-
ure 5.1 on page 55). If the disease is not caused by a homozygous mutation, it
is also imaginable that the underlying pattern of inheritance is dominant and the
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Figure 5.1.: Reconstruction of haplotype alleles in Family 2 for chromosome 2 from
microsatellite marker from D2S2254 to D2S1326 (Chr2: 119,988,825 - 139,923,024).
Apparently, all patients inherited the same set of alleles (from D2S283 to D2S1326:
Chr2: 121,643,494 - 139,923,024) further narrowing down the possible disease locus
on chromosome 2. These results imply, that OPDM could be caused by compound
heterozygosity in this family.
causative genetic variant is heterozygous. Since none of the parents are aﬀected, ei-
ther incomplete penetrance, a germ-line mutation or genetic mosaicism would have
to underlie the condition in this family. Still, chromosome 2 at around 150cM would
be a good candidate region, presenting with a LOD-score greater than 1 (top score
for a dominant model).
5.3.2. Candidate Genes on chromosome 2
In summary, special attention was put on the list of genes inside the conceivable
disease locus on chromosome 2 mapped to the region from rs12711539 and rs344689
(chromosome 2: 121,837,519 - 140,100,106) by genotype analysis based on SNP
genotyping array and whole exome sequencing data (see Figure 4.5 on page 27) which
was further mapped by recombinant haplotype analysis done in Dresden by Prof.
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Angela Hübner to D2S283 to D2S1326 (chromosome 2: 121,643,494 - 139,923,024) as
displayed in ﬁgure 5.1 on page 55. None of the genes found in table 4.1 on page 28 are
striking candidate genes according to their gene function, yet the most likely would
be MYO7B, encoding the protein myosin VIIB. Myosins are molecular motors that
use energy from adenosine triphosphate (ATP) hydrolysis to generate mechanical
force upon their interaction with actin ﬁlaments. There are seven vertebrate myosin
classes, the conventional myosin II and the unconventional myosins I, V, VI, VII,
IX and X. Unconventional myosins have a structurally conserved head that moves
along actin ﬁlaments. Their highly divergent tails are presumed to enable them to
transport cargo [126]. MYO7B is expressed in small amounts in skeletal muscle,
its main function, still not fully understood, however seems to be in the small and
large intestines as well as the kidneys, where it is highly expressed [127]. Exome
sequencing of three siblings from Family 2 did not identify any rare, protein altering
variants within the locus from rs12711539 and D2S1326 (chromosome 2: 121,837,519
- 139,923,024) that are shared by all three patients.
5.3.3. Possible Compound Heterozygous Variants
Exome sequencing revealed a number of variants with two or more of them being
found in one single gene. Therefore, these could be compound heterozygous and
causative for a recessive inheritance. Namely, these are variants in the genes MUC2,
MBD3L3, FBN3 and TTN and are listed in Table 4.5 on page 37. MUC2 encodes
a member of the mucin protein family, which are large glycoproteins produced by
many epithelial tissues. Mucin 2 is secreted by the gut mucosa and forms an insoluble
barrier to protect the intestines [128]. The two detected variants are c.5014T>G,
p.(S1672A) and c.4876A>T, p.(I1626F) (transcript variant NM_002457.3). In 4362
control alleles from the ExAC browser, the c.50T>G variant can be found twice in
a heterozygous state whereas the c.4876A>T is not listed. However, there is a huge
number of homozygous missense variants listed in the ExAC browser. In a nutshell,
MUC2 is not a good candidate gene by it's function and by the identiﬁed variants.
MBD3L3 encodes the protein methyl-CpG-binding domain protein 3 like 3 and
there are no studies up to date about its cellular function. Methyl-CpG binding
domain protein 3, however, is a subunit of the NuRD (Nucleosome Remodeling
Deacetylase), a multisubunit complex with ATP-dependent chromatin remodeling
and histone deacetylase activities [129]. This complex is crucial for the regulation
of chromatin structure and promotion of transcriptional repression [130]. Variants
in this gene have not been associated with any diseases yet. The two identiﬁed vari-
ants in MBD3L3 (NM_001164425.1), located on chromosome 19, are c.622A>G,
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p.(R208G) and c.619T>G, p.(C207G) both of which are not listed in the dbSNP-,
EVS5400- and the 1000genomes database. The ﬁrst variant is a substitution of the
positively charged amino acid arginine with the hydrophobic glycine. This position
is the last amino acid before the stop codon in MBD3L3 and conserved in rhesus
and dog. The second change alters a hydrophobic cysteine to a likewise hydrophobic
glycine. Eventually, a disulﬁde bond could get lost and therefore alter the protein's
tertiary structure. These variants are both not listed in the ExAC-browser database
but ExAC-coverage of this gene is very bad in general (average: 5.947) resulting
in unreliable data. However, the linkage analysis for this region on chromosome 19
results in a negative LOD score of less than -2. Most interestingly, individuals from
Finland (OPDM7) and Canada (OPDM8) carry the same pair of variants, whereas
an individual from the UK (OPDM6) is homozygous for the c.622A>G, p.(R208G)
change. Even though the linkage analysis implies that the other two aﬀected indi-
viduals from Family 2 do not carry the same two variants Sanger sequencing should
be done to verify the changes followed by segregation analysis in Family 2.
Two other variants were detected in the gene FBN3 (NM_032447.3) which is
located on chromosome 19 and encodes the protein ﬁbrillin 3. This extracellu-
lar matrix macromolecule assembles into microﬁbrils in a vast number of con-
nective tissues, especially during fetal development [131]. Polycystic ovary syn-
drome susceptibility was linked to a dinucleotide repeat expansion in Intron 55 by
a genomewide association study (OMIM: %184700) [132]. The two variants are
c.6397G>A, p.(Gly2133Ser) and c.5399G>A, p.(Gly1800Asp). The ﬁrst one sub-
stitutes the non-polar amino acid glycine with the uncharged polar serine and the
second one substitutes glycine with the likewise uncharged polar asparagine. Amino
acid position 2133 is highly conserved but some other species, including chicken, ze-
braﬁsh and xenopus tropicalis, express serine instead of glycine at position 1800. The
c.6397G>A variant can be found 21 times in the ExAC browser, and c.5399G>A
20 times. Linkage analysis revealed a LOD-score of around -1 for this region on
chromosome 19, implying that the other two aﬀected siblings might not carry the
same pair of variants within FBN3. Additionally, it is more likely that mutations
in a cytoplasmic or nuclear protein are causative for OPDM as microscopic studies
on muscle tissue showed a clear intracellular pathology. Deleterious missense muta-
tions are expected to result in a loss of function and result in a gene-function related
phenotype. Therefore, these two variants were not investigated any further.
Finally, a number of 4 heterozygous rare and protein altering variants in the gene
TTN (NM_133378.4) were detected, shared by OPDM3, OPDM4 and OPDM5:
c.92522G>A, p.(C30841Y) (listed 12 times in a heterozygous state in the ExAC-
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browser), c.87147T>A, p.(D29049E) (listed 345 times in a heterozygous state in the
ExAC-browser), c.11138C>G, p.(T3713S) (listed 359 times in a heterozygous state
in the ExAC-browser) and c.1267A>C, p.(S423R) (listed once in a heterozygous
state in the ExAC-browser). Additionally, c.87147T>A and c.11138C>G are listed
in dbSNP and have a frequency of about 0,24% and c.73031G>A of 0,02% according
to the ESP5400 database, the other one is not listed in any of these databases as
shown in table 4.5 on page 37.
Mutations in the titin gene are associated with a number of neuromuscular dis-
orders such as autosomal recessive (AR) limb-girdle muscular dystrophy 2J (MIM
#608807) [133] and it's milder form, the autosomal dominant (AD) tibial muscu-
lar dystrophy (MIM #600334) [73], where patients are heterozygous for the muta-
tions causing AR LGMD2J. They can also cause early-onset myopathy with fatal
cardiomyopathy (MIM #611705) [134]. Cases with inherited hypertrophic (MIM
#613765) or dilative (MIM #604145) cardiomyopathy have also been described [72].
Most of these skeletal muscle titinopathies are caused by truncation and other loss
of function alleles in the most distal M-band (C-Terminus) region of titin, commonly
with autosomal recessive inheritance [135].
Evaluation of assigning pathogenicity to single variants in the titin gene is chal-
lenging as genetic polymorphisms are common and associated with a number of
conditions - a study by Herman et al. showed, that heterozygous truncating mu-
tations (nonsense-, frameshift- and splicing mutations) in the titin gene occur in
about 3% of apparently healthy individuals [72]. For truncating variants, a length
dependent algorithm has been established to estimate the chance of being causative
for nonischemic dilated cardiomyopathy [136]. In neuromuscular disorders, how-
ever, this is much more diﬃcult, as the number of patients with conditions caused
by aberrations in the titin gene are rare and most are missense and not nonsense
mutations. A second problem, especilly with next-generation sequencing of titin, is
the challenge of mapping short reads against such a repetitive sequence leading to
false positive variants being called [135]. Filtering out variants that occur often 
the so called in-house frequency  tries to tackle this issue but cannot completely
solve it.
The c.11138C>G, p.(T3713S) and c.1267A>C, p.(S423R) variants are located
towards the N-terminal end of the titin protein and c.92522G>A, p.(C30841Y) as
well as c.87147T>A, p.(D29049E) within the elastic I-band region. Therefore they
are most likely not causing any of the neuromuscular conditions described above.
Additionally, some of the variants are listed with a higher frequency in the ExAC-
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browser, decreasing the likelihood of pathogenicity. Conclusively, these variants were
also excluded from further studies.
5.3.4. Summary
In Family 2, a very likely disease locus has been identiﬁed by reconstruction of
recombinant haplotype alleles which was mapped to chromosome 2: 121,837,519 -
139,923,024 and patients would be expected to be compound heterozygous as they
inherited diﬀerent alleles from their parents. Homozygosity mapping did not uncover
any larger shared homozygous regions on chromosome 2 providing evidence, that
OPDM can be mapped to the locus described above. However, no candidate genes
could be identiﬁed, indicating, that similarly to Family 1, a more complex genetic
reason is underlying OPDM in this family. Conceivable mechanisms would be larger
deletions as well as copy number variations or repeat expansions as found in myotonic
dystrophies or OPMD [137], [138], [139]. Larger insertions cannot be detected by
next generation sequencing techniques as they provide too many mismatches to
the reference assembly for alignment tools. Conclusively, further studies such as
sequencing of repeats will be necessary to ﬁnd the causative mutation for OPDM in
this family.
5.4. Possible Genetic Causes for OPDM in Individual OPDM
VI
5.4.1. NEB c.21044C>G, p.(S7015C) and c.22122C>G, p.(D7374E)
Whole exome sequencing identiﬁed 2 variants of unknown signiﬁcance in the
gene NEB (NM_001164508.1) encoding nebulin, c.21044C>G, p.(S7015C) and
c.22122C>G, p.(D7374E) which are located within the high linkage area on Chro-
mosome 2. As previously mentioned, mutation in the NEB gene are associated
with autosomal recessive Nemaline myopathy (OMIM #256030), a muscle condi-
tion where patients usually exhibit generalised hypotonia at birth also aﬀecting
respiratory muscles. Proximal limb muscles are usually weaker initially, but distal
limb muscle weakness eventually occurs. The facies is commonly myopathic with a
high-arched palate and extraocular muscles spared. Chest deformities, hyperlordosis
and scoliosis develop in some cases at puberty. Deep tendon reﬂexes are usually de-
creased or absent. None of the patients initially reported showed cardiac involvement
[140]. Histopathological studies usually show nemaline bodies which are thread- or
rod-like structures. Also, in 2007 a novel entity caused by homozygous missense
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variants in NEB was described in four Finnish families where aﬀected individuals
only presented with mild distal myopathy and no nemaline bodies were seen in his-
tological examinations[141]. The NEB c.21044C>G, p.(S7015C) and c.22122C>G,
p.(D7374E) variants were rare with frequencies of 0.004122 and 0.009407 in the
ESP respectively but are also listed in dbSNP. However, the ExAC-browser lists 411
heterozygous and 4 homozygous carriers for the c.21044C>G-variant as well as 1085
heterozygous and 13 homozygous control individuals for the c.22122C>G-variant.
To conﬁrm the compound-heterozygous state of the variants the changes would have
to be segregated in the families or tested by cloning and sequencing NEB. However,
DNA from the parents was not available. Looking at both the Nemaline-Myopathy
phenotype and the frequencies, it is unlikely that the variants mentioned above are
the underlying genetic defects in this patient.
5.4.2. Variants in the TTN gene
A total number of four variants within the TTN -gene, encoding titin, a gigantic
structural protein of muscle ﬁbres and the largest human protein , could be identiﬁed:
c.42310C>T, p.(P14104S), c.18427C>T, p.(R6143W), c.11866A>T p.(I3956F) and
c.1492G>A, p.(V498I) (NM_133432.3). Diﬃculties with assigning pathogenicity to
mutations in the TTN gene are discussed in chapter 5.3.3 on page 56.
Most of these skeletal muscle titinopathies are being caused by truncation and
other loss of function alleles in the most distal M-band (C-Terminus) region of
titin, commonly with autosomal recessive inheritance [135]. The c.18427C>T,
p.(R6143W), c.11866A>T p.(I3956F) and c.1492G>A, p.(V498I) variants, however,
are located towards the N-terminal end of the titin protein and the c.41935C>T,
p.(P13979S) change within the elastic I-band region most likely not causing one of
the conditions described in chapter 5.3.3 on page 56. Additionally, the phenotype
of tibial muscular dystrophy or limb-girdle muscular dystrophy 2J diﬀer decisively
from that of OPDM. To further evaluate these variants, their allele frequency was
determined based on the data from the ExAC-browser which lists exome data
from around 60,000 controls. c.42310C>T is found in 407 healthy individuals in a
heterozygous- and once in a homozygous state. The c.18427C>T-variant is rare and
was only found 6 times in a heterozygous state. There were 659 heterozygous and 3
homozygous controls listed for the c.11866A>T-change and 1801 heterozygous and
21 homozygous individuals for the c.1492G>A-variant. These frequencies almost
certainly exclude a causative association between the variants and the patient's
phenotype. Therefore, carrier status of the parents was not tested to see which
changes are compound heterozygous.
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5.4.3. RYR1 : c.8382C>G, p.(Y2794X)
Exome sequencing detected a truncating variant in RYR1, encoding the protein
ryanodin receptor 1. Mutations in this gene consisting of 106 exons are associ-
ated with autosomal dominant central core myopathy (MIM #117000), autosomal
recessive minicore myopathy with external ophthalmoplegia (MIM #255320) and
malignant hyperthermia susceptibility (MIM #145600) [74], [75],[76],[77].
Central core disease (CCD) is an autosomal dominant myopathy presenting in in-
fancy and involving predominantly proximal muscles [142]. Muscle weakness of the
lower limb is the most important feature and can be slow- or non-progressive. Diag-
nosis is made by muscle biopsy showing amorphous central areas (cores). Mutations
in RYR1 identiﬁed so far are missense variants and small in-frame deletions which
are mostly located in the C-terminal domain. Multi-minicore disease (MmD) is quite
similar with the only distinct diﬀerences being the pattern of inheritance and the dif-
ferent size of the histological lesions in skeletal muscle ﬁbres [74]. Most likely, patient
OPDM VI does not have a congenital myopathy with cores in the muscle biopsy,
otherwise DNA would not have been provided as an OPDM patient. Additionally,
the nonsense-mutation p.(Y2794X) would lead to nonsense-mediated decay of the
mRNA and therefore exclude a dominant negative eﬀect. The ExAC-Browser lists
all variants in about 120,000 control alleles (http://exac.broadinstitute.org).
It lists 50 loss of function variants (LoF) in the RYR1 -gene in healthy individuals,
resulting in a pLI (probability of LoF intolerance) of 0.00. Therefore, it is unlikely,
that the variant described above results in haplotype insuﬃciency and is causing the
muscle phenotype in this patient. As the parents of the patients were reported to be
healthy, it would also be crucial to test them for the carrier status and conﬁrm that
the variant is de novo to argue for a deleterious eﬀect. It might also be the case that
a second mutation within the RYR1 gene was missed by whole exome sequencing
leading to autosomal recessive MmD - but even then the phenotype would not ﬁt
to OPDM.
5.4.4. Summary
All in all, none of the variants described above is very likely to be responsible for the
muscle condition in this patient if she presents with a OPDM phenotype including
those on chromosome 2. There were no mutations detected within the novel disease
locus on chromosome 10. As the most complex and largest genes in the human
genome including TTN, RYR1, NEB and DMD are associated with neuromuscular
disorders it is foreseeable, that variants are being detected here. A recent study
has identiﬁed variants of unknown signiﬁcance in 32% of 177 samples in these and
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other large NMD-genes [143]. If mutations in the same gene are responsible for the
disease in Family 1 and OPDM VI it it understandable that they are missed by
whole exome sequencing.
5.5. Possible Genetic Causes for OPDM in Individual OPDM
VII
5.5.1. Variants Within High Linkage Areas
A number of variants were identiﬁed within the high linkage area on chromosome 2
and the deﬁned disease locus on chromosome 10. Two changes within the gene
GLI2 (NM_005270.4) were identiﬁed, c.4332G>A, p.(M1444I) and c.4333C>T,
p.(L1445F) at genomic locations 121,747,822 and 121,747,823 on chromosome 2.
Mutations in GLI2  encoding a zinc ﬁnger and transcription factor of Sonic hedge-
hog signaling  are associated with various kinds of malformation (OMIM #610829,
#615849) [78], [79]. Both the c.4332G>A and the c.4333C>T change can be found
20 times in a homozygous state in healthy individuals according to the ExAC-
browser, therefore excluding pathogenicity.
Two variants were identiﬁed within the shared recombinant haplotype region on
chromosome 10. The ﬁrst is a change in the third exon of POLR3A (NM_007055.3):
c.275G>C, p.(C92S) and thus located very close to the centromeric recombination
point of the disease haplotype. Even though mutations in POLR3A are associated
with recessive hypomyelinating leukodystrophy (OMIM #607694) [69], it is conceiv-
able that they are also responsible for a completely diﬀerent phenotype like OPDM.
However, this variant has a frequency of 0.0002 according to the 1000genomes
database as it was identiﬁed on 1 out of 5008 alleles. The ExAC browser lists
34 individuals carrying the variant in a heterozygous state. Considering an autoso-
mal dominant trait or de novo status, the minor allele frequency of 0.0002801 is too
high to consider this variant to be causative for the patient's phenotype.
The second change found within the disease locus isNRG3 : c.901G>A, p.(E301K).
A detailed description of the gene function as well as phenotypes associated with
mutations can be found in chapter 5.2.4 on page 53. This variant is reported to
have a minor allele frequency of 0.002417 in the ESP and 0.0023 in the 1000genomes
database, meaning, that around 1 in 218 individuals is heterozygous for this vari-
ant, which is far too many for a dominant trait. The ExAC browser also lists 9
homozygotes, thus conﬁrming that c.901G>A is a benign polymorphism.
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5.5.2. RYR1 : c.10025C>T, p.(A3342V)
A variant within the RYR1 (NM_000540.2) was detected in patient OPDM VII,
c.10025C>T, p.(A3342V). Most interestingly, this is the second variant found in
a patient with suspected diagnosis of OPDM. This variant substitutes the non-
polar amino acid alanine with the likewise non-polar valine which most likely does
not disrupt the protein structure. This variant is not listed in the ESP- and has
a minor allele frequency of 0.0002 according to the 1000genomes database. The
ExAC browser lists 52 control alleles carrying this variant resulting in a minor allele
frequency of 0.0004323. This number is far too high for an autosomal dominant
trait or de novo status. Therefore, this variant was considered not to be associated
with the patient's muscle condition and consequently not segregated in the patient's
family.
5.6. Possible Genetic Causes for OPDM in Individual OPDM
VIII
5.6.1. Variants in the TTN -Gene
Whole exome sequencing uncovered three variants in gene TTN (NM_001267550.1)
namely c.107098G>A, p.(D35700N), c.16303G>A, p.(V5435M) and c.10879G>A,
p.(V3627I). The ExAC browser lists 673 heterozygotes and 7 homozygotes for the
c.16303G>A, p.(V5435M) variant resulting in a minor allele frequency of 0.005636.
Therefore, this change has to be benign to the gene. The other two variants are
not listed in in the 1000genomes-, the EVS- and the ExAC- database. However,
without the patient's parents' DNA it was not possible to proof biallelic location of
the c.107098G>A and the c.10879G>A change. Similarly to the discussion of the
changes within the titin gene found in patients OPDM III, OPDM IV, OPDM V
and OPDM VI (5.3.3 on page 56), the latter were not thought to be the underlying
genetic cause for this patient's muscular condition.
5.6.2. MYOT : c.655C>T, p.(R219X)
Exome sequencing uncovered a variant in the gene MYOT, associated with Limb-
Girdle Muscular dystrophy type 1A (LGMD1A, MIM #159000), Myoﬁbrillar My-
opathy (MIM #609200) and Spheroid Body Myopathy (MIM #182920), all of which
are inherited in an autosomal dominant way. Patients with LGMD1A exhibit a prox-
imal pattern of muscle weakness progressing to include distal limb-girdle muscles.
CK levels are elevated up to 9-fold of the normal upper limits. Biopsies of aﬀected
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individuals show myopathic changes such as variations in ﬁber size, ﬁber splitting,
and other hallmarks of degeneration as well as a large number of rimmed vacuoles. Z-
line streaming, similar to that seen in nemaline myopathy, was also observed [144].
Although some individuals with LGMD1A exhibit a distinctive nasal, dysarthric
pattern of speech [144], the predominantly proximal pattern of muscle involvement
is quite distinct from the phenotypical presentation of OPDM.
Myoﬁbrillar myopathies (MFMs) are a genetically heterogeneous group of muscu-
lar disorders. They are characterised by a pathologic pattern of myoﬁbrillar degra-
dation and accumulation of Z disc proteins [145]. MFM due to mutations in MYOT
(myotilin) includes progressive distal muscle weakness and peripheral neuropathy
with hyporeﬂexia. The age of onset is usually in the ﬁfties or sixties. Cardiac in-
volvement, as seen in some OPDM patients occurs in a number of individuals. Mus-
cle biopsies show abnormal muscle ﬁbers deposits consisting of amorphous granular
and/or hyaline material. Some hyaline structures are thought to comprise beta-
pleated amyloid sheets. Electron microscopy studies show smear like aggregates
of dense material emerging from Z discs [90]. Although patients exhibit a distal
limb-girdle weakness, the phenotype of myoﬁbrillar myopathy caused by mutations
in MYOT diﬀers from that of OPDM as these patients typically do not have any
pharyngeal or ocular involvement.
A subgroup of MFM caused by mutations in the MYOT gene is called spheroid
body myopathy due to accumulation of myoﬁlamentous material within individual
muscle ﬁbers [146], [91]. Patients present ﬁrst in adolescence and proceed to some
motor incapacitation, but life span is not shortened. Muscle weakness is predomi-
nantly proximal, almost excluding a misdiagnosis of OPDM.
The variant found in patient OPDM VIII inside the myotilin gene is not easy
to evaluate as it is the heterozygous nonsense mutation c.655C>T, p.(R219X) in
exon 5 (of 10) of the MYOT gene (transcript variant NM_006790.2). To discuss,
if a heterozygous missense mutation can cause a dominant inherited condition the
molecular basis of dominance has to be understood. First, protein levels can be
reduced by a phenomenon called haploinsuﬃciency. This is, when the monoallelic
expression of a gene is not enough to result in a normal phenotype [147]. This phe-
nomenon, common in cancer progression, however, is rare in other ﬁelds of medicine
when focussing on single nucleotide alterations and smaller deletions. Second, pro-
tein function can be altered, producing a gain or loss of function. A loss of function
could be exemplary explained, when both the wildtype and the mutated protein
get incorporated into a structural protein causing a lack of stability such as in
Ehlers-Danlos syndrome [148]. Gain of function, such as in Chronic mucocutaneous
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candidiasis disease caused by mutations in the gene STAT1, results in this condi-
tion through increased activation of some cytokines thus inhibiting the development
of a subgroup of T-cells [149]. The missense variant p.(R219X) is very likely not
altering the protein function as in most cases with nonsense mutations the mRNA
is eliminated by nonsense-mediated decay resulting in no protein production at all
[150].
The only remaining explanation how this variant can cause a neuromuscular phe-
notype is haploinsuﬃciency. This is a phenomenon that appears to be extremely
rare in autosomal dominant neuromuscular disorders with only a small number of
publications where authors claim that haploinsuﬃciency is the underlying genetic
mechanism as by Benedetti et al. 2007 [151]. A rough prediction, if loss of function
variants result in haploinsuﬃciency can be derived from the pLI-score (probability of
LoF intolerance) provided by the ExAC browser. It is assumed that there are three
classes of genes with respect to tolerance to LoF variation: null (complete toler-
ance to LoF), recessive (heterozygous LoFs tolerance), and haploinsuﬃcient (where
heterozygous LoFs are not tolerated). Observed and expected LoF variants counts
are used to determine the probability of LoF intolerance (pLI). The closer pLI is
to one, the more LoF intolerant the gene appears to be. A pLI ≥ 0.9 is considered
an extremely LoF intolerant set of genes [152]. MYOT has a pLI of 0.00, therefore
it is very likely to tolerate the loss of one allele which makes it unlikely that the
heterozygous MYOT p.(R219X) variant could cause OPDM in this patient.
5.6.3. MEGF10 : c.1564G>A, p.(G522R)
A second heterozygous variant, uncovered by whole exome sequencing in this pa-
tient is c.1564G>A, p.(G522R) in the gene MEGF10. Mutations in MEGF10 are
associated with autosomal recessive early-onset myopathy, areﬂexia, respiratory dis-
tress, and dysphagia (EMARDD, MIM #614399) as well as recessive congenital
myopathy with minicores [86], [87]. Both conditions are not very likely to cause
a phenotype similar to that of OPDM. Additionally, the c.1564G>A, p.(G522R)
change was found twice in a homozygous status in control individuals according to
the ExAC browser. Therefore, this variant is most likely not associated with the
muscle condition in this patient.
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5.6.4. MATR3 : c.313C>T, p.(R105C)
5.6.4.1. Can Distal Myopathy Mimic OPDM?
As a change in the gene MATR3, associated with vocal cord pharyngeal distal my-
opathy (VCPDM, OMIM #606070), was detected in patient OPDM VIII, it ﬁrst
needs to be discussed, if VCPDM can mimic the phenotype of OPDM. In VCPDM
patients the mean age of onset is 42.2 years (range: 30-55 years) in [153]. Patients
exhibit a speciﬁc pattern of muscle weakness: Legs seem to be more severely af-
fected than the arms. Weakness in the distal limbs is commonly more pronounced
than in the proximal compartments. Still, most patients remain ambulant for a long
time. Dysphagia and voice pathology is common but ocular muscle involvement
has not been described so far. Interestingly, the Achilles reﬂex was absent in all
patients assessed by Müller et al.. Histopathology shows myopathic changes such
as ﬁber size variation, minor fatty replacement and internal nuclei in all patients.
Additionally, subsarcolemmal rimmed vacuoles, also observed in hereditary inclu-
sion body myositis [154], OPMD [155], and other myopathies as well as atrophic
ﬁbers consistent with denervation, can be seen in most patients. Ultrastructural
studies showed sparse and small tubular aggregates but no ﬁlamentous inclusions
[156]. Patients with VCPDM usually present with myopathic changes in electromyo-
graphical assessments [157]. Pathological spontaneous activity was found in some
patients [153]. Creatine kinase (CK) serum levels were generally within twice the
upper limits of normal levels. [153].
All these pathologic ﬁndings are consistent with the clinical diagnosis of OPDM
except that ocular muscles are usually spared in patients with VCPDM [157]. There-
fore, it is not farfetched that patients with VCPDM can clinically be diagnosed with
OPDM and consequently, the detected mutation in the gene MATR3 should be
considered a good candidate gene in this patient.
5.6.4.2. Evaluation of the Mutation
The c.313C>T, p.(R105C) in the Matrin 3 gene, transcript variant (NM_018834.5)
found in this patient was predicted to alter the strength of two splice acceptor sites
and cause a substitution of the polar and positively charged amino acid arginine
with the nonpolar cysteine. However, this variant is located in a non-canonical
transcript and the proportion of expression has not been published, yet. If this
region would be coding in only a small percentage it would be diﬃcult to argue
that this mutation is deleterious. However, if the altered strength of two splice
acceptor sites caused by this variant is shifting the ratio towards the transcripts
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including this region to the protein coding part it would most likely disrupt the
protein structure. Only one mutation in the MATR3 gene, found in patients from
Tennessee., USA, Bulgaria, Germany and Japan, namely p.(S85C), is reported to
cause autosomal dominant vocal cord pharyngeal distal myopathy (VCPDM) [94].
Most interestingly, the variant is not listed in the ExAC browser and the pLI is 1.00
as there is not a single LoF variant in the MATR3 gene found in control individuals.
This implies, that the observed variant is most likely deleterious if this transcript
is expressed in skeletal muscle. No speciﬁc diagnostic criteria for VCPDM has
been determined yet as immunohistochemical staining shows no diﬀerences between
patients and controls concerning subcellular location inside the nuclei of muscle cells
as well as expression levels determined by real-time PCR and Western-Blot analyses
[153]. To further investigate the case, cDNA analyses to determine the ratio of
transcript variants as well as quantiﬁcation of Matrin 3 protein as well cDNA have
to be done. In summary, the c.313C>T, p.(R105C) variant detected in the gene
MATR3 is considered a good candidate gene in this individual.
5.6.5. Variants Within the High-Linkage Areas
In addition to variants in genes known to cause neuromuscular diseases, special in-
terest was put on the mapped disease locus on chromosome 10 as well as on the high-
linkage area on chromosome 2. No single rare and protein-altering change was seen
at chromosome 10: 79,750,884 - 85,566,388 and only the TTN -changes discussed
above were interesting among those detected on chromosome 2. Conclusively, the
best candidate variant in this patient is MATR3 c.313C>T, p.(R105C) and needs
to be further evaluated by expression analyses, immunohistochemical stainings and
screening of patients with a similar phenotype for this particular mutation.
5.7. How Disease Causing Variants can be Missed by
Whole-Exome Sequencing
5.7.1. Technical Issues
As exome sequencing of patients from two larger families as well as 2 individual pa-
tients did not detect convincing candidate genes it needs to be discussed, how disease
causing variants can be missed by this technology. First, there are a number of tech-
nical issues which should be considered when analysing WES data. Obviously, only
the protein-coding parts of the genome are covered by this method and variants in
the gene's noncoding as well as intergenic regions cannot be identiﬁed. Additionally,
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some coding regions of rarely expressed transcript variants might not be targeted
by exome sequencing libraries. Also, only around 92% of the exome is currently en-
riched by modern kits as it is diﬃcult to design hybridisation probes for some coding
regions, especially repetitive elements and GC rich sequences. Furthermore, even
coverage for targeted coding exons is not 100% accurate with some regions being
poorly and some being not covered at all. Modern established sequencing pipelines
reach a coverage of around 97-98% with a minimum read depth of 20x which is
required for conﬁdent variant calling [36], [158]. As the bioinformatical pipeline
used in this study has not been validated and tested against diﬀerent approaches for
coverage as well as sensitivity and speciﬁcity of variants being called the coverage is
expected to be less than 97%. The importance of these technical issues was high-
lighted by a study displaying that especially some exons of genes associated with
neuromuscular disorders are diﬃcult to enrich for next-generation sequencing [159].
They also reported that approximately 10-20% of the 92% of targeted exons had
low or zero coverage in their whole exome database [159]. The main reason for the
incomplete coverage is GC-rich regions which are a challenge for exome enrichment
kits that use clonal ampliﬁcation of templates. These commonly comprise the ﬁrst
exons of protein coding genes. As PCR is required for these techniques, AT-rich
and GC-rich target sequences may be underrepresented in genome alignments and
assemblies which may result in very low coverage [160], [161], [162]. All in all, this
may well be an explanation, why this study was not able to identify the genetic
reason for OPDM. However these issues are mitigated by the fact, that the disease
could be mapped and uncovered exons within the linkage area were analysed by
Sanger sequencing.
5.7.2. Repeat Expansions
A second issue, why exome sequencing studies might fail to identify causative genetic
aberration, could be that a repeat expansion is underlying the inherited condition.
This is likely in OPDM as discussed in chapter 5.2 on page 51. Identiﬁcation of
large expansions can fail on diﬀerent stages during the process of next-generation
sequencing [163]. First, hybridisation of patient DNA to the probe for target enrich-
ment could be impaired and result in no coverage. Second, as target enrichment is
based on PCR, the polymerase might struggle which results in poor coverage. Third,
sequencing itself is challenging for repeat regions because most next-generation se-
quencing platforms, as the Illumina sequencing system used in our studies, rely on
reading signal from bulk DNA populations, like Sanger sequencing does. Therefore
they are limited by the loss of sequence phase coherence - a particular problem of the
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often GC-rich repeat regions. Conclusively, even the best ampliﬁcation based NGS
technology cannot sequence alleles with expansions of around 100 repeats [164]. And
ﬁnally, reads covering an expanded repeat might not be aligned by software tools
due to the number of mismatches to the reference genome as the maximum read
length is 100bp using an Illumina platform. In summary, standard approaches for
NGS enrichment will not always work in high-repeat genomic regions and preferen-
tial use of alternative technologies such as the PacBio system should be considered
when a repeat expansion is likely to be the underlying genetic cause of a disease.
5.7.3. Indels
Additionally insertions and deletions (so-called indels) could be causative for OPDM
and be missed by whole-exome sequencing. There are two main diﬃculties in identi-
fying indels: First, next-generation sequencing technology is susceptible to produce
indel artifacts, especially 1 bp heterozygous indels inserted to or deleted from long
poly-A or poly-T runs (homopolymers) [165], [166]. And second, alignment of reads
spanning indels is challenging with many of them being misaligned, resulting in
bad coverage which might not be enough for a conﬁdent variant call [167], [165].
Unsurprisingly, a recent study has demonstrated that the concordance between dif-
ferent software tools to call indels is as little as 30% [25]. Thus, if the causative
genetic variation for OPDM was an indel, it is likely to be missed by whole-exome
sequencing.
5.7.4. Copy Number Variations
A special subset of indels are structural variants called copy number variation mean-
ing very large insertions or deletions ranging up to several megabases in size. In
recent years as detection tools improved, their role in inherited diseases as well as
in cancer has been highlighted [168], [169], [170]. There are two main options to
identify copy number variations. One is detecting linkage disequilibrium by SNP
genotyping array data meaning that certain SNPs ﬂanking CNV regions are inher-
ited combined (linkages) more or less often than would be expected judging by their
distance apart in the genome [171]. The other is a read-depth approach, where the
the mapping ratio of next-generation sequencing read counts relative to a reference
genome is determined for detection of copy number variations [172]. At the time of
bioinformatical processing of the exome-sequencing data for this study, many of the
software tools for detection of copy number variation were not available. Therefore
these structural variations could not be identiﬁed, if present at all, and programs like
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CNV-seq, Pindel or ExomeDepth should be included in a reanalysis of whole-exome
sequencing data [173], [174], [175].
5.7.5. Bioinformatic Diﬃculties
Also, bioinformatical analysis of exome-sequencing raw data poses problems and
needs to be discussed as the choice of annotation tool and variant callers can result
in various discrepancies. In one study, two diﬀerent transcript sets  RefSeq and
Ensemble  were used as a basis for annotation and the authors only found 44%
agreement in annotations for loss of function variants [176]. The same study also
showed, that only 65% of loss of function changes and 87% of all variants in the
coding regions were matching when comparing results from two annotation software
tools annovar and VEP (Variant Eﬀect Predictor, [177]), implying that there is a
huge number of false negative variants. A similar study demonstrates that combina-
tion of diﬀerent read aligners with variant calling software tools vary in performance
[178]. They also show huge discrepancies for indels and SNPs, as all alignment tools
use diﬀerent algorithms coming with diverging strengths and weaknesses. For ex-
ample the usage of gapped alignment algorithms - i.e. the ability of allowing a gap
in a read compared to the reference sequence - is important for indel detection on
the cost of eﬃciency and time [59]. Faster alignment tools will therefore identify
less indels and might miss the causative genetic change.
Additionally, the eﬀect of grouped or single sample variant calling needs to be dis-
cussed as the exome sequencing data has been analysed one at a time. Pooled sample
variant calling allows the use of reads across all samples of a batch at a position to
determine the presence of a polymorphism, markedly improving the sensitivity. One
study showed that grouped sample variant calling resulted in 4.30% more detected
SNPs [179]. To sum it up, the perfect bioinformatical pipeline does not exist and
all combinations of software tools, like Mosaik Aligner and Varscan/Dindel variant
caller as used in this study, have their weaknesses and will not be able to detect all
present variants.
5.7.6. Familial Locus Heterogeneity
A recent study highlighted the problem of familial locus heterogeneity, meaning
that two or more disease-causing mutations are responsible for the same phenotype
in a larger family. Rehman et al. presented 10 consanguineous Pakistani families
with autosomal recessive hearing loss due to mutations in two or more genes [180].
They concluded that familial locus heterogeneity occurs in around 15% of families in
their collection, making it a common cause of failure in next-generation sequencing
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projects. In such cases, linkage analysis would result in decreased LOD-scores. It
might therefore be a good strategy to obtain the MLOD score for each pedigree
from simulations using information on the pedigree structure, mode of inheritance,
aﬀection status, penetrance and availability of genotype data. The MLOD score
is the highest possible LOD score obtained for all replicates. If the actual LOD
score does not reach the level of the simulated MLOD score it is reasonable to
assume familial locus heterogeneity and analyses should be repeated for the diﬀerent
branches of a family. This could be the underlying cause of the low LOD score in
Family 1 which was expected to be higher due to the size of the pedigree. Further
analyses as suggested above should be performed to exclude this phenomenon in
Family 1.
5.8. Options to Find the Genetic Cause of OPDM
5.8.1. Upcoming Advances in Next-Generation Sequencing
As this study was unable to identify the genetic cause or causes of OPDM even
though two disease loci could be identiﬁed, further options need to be discussed how
to solve this case.
First, some of the technical issues, discussed in chapter 5.7.1 on page 67 are being
tackled everyday and there will be advances in next-generation sequencing technol-
ogy that will solve many of these issues. One of the most interesting advances will
be the improvement of real-time DNA sequencing from single polymerase molecules
such as the PacBio Sequencing platforms [181]. This sequencing platform produces
reads with an average length of 10kb with half the amount of reads being longer
than 20kb [182]. Therefore it would be ideal for the detection of larger aberra-
tions such as indels or repeat expansions and should be considered the number one
choice for further studies on OPDM. An alternative sequencing platform, which is
currently being established and improved, is the the Oxford Nanopore which shows
great potential regarding accuracy as well as cost- and time eﬃciency. From ﬁrst
studies, a proof of concept and improvements by using genetically improved biolog-
ical pores in 2009 to the introduction of the minION sequencing device of the size
of a palm being commercially available since May 2015 this technology is expected
to revolutionise the ﬁeld of high-throughput sequencing [183], [184]. If ﬁrst studies
prove a higher sensitivity in comparison with established platforms from Illumina
and Roche it might be a good option for further sequencing projects on OPDM.
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5.8.2. Analysis for Copy Number Variations
As discussed in chapter 5.2.3 on page 52, copy number variations are an underesti-
mated genetic basis of neuromuscular disorders and the bioinformatic pipeline used
in this study is not able to detect them. There are two main strategies how to call
CNVs, one is from paired data where the ratio of read counts from a test- and a
control sample is used to detect regions that deviate from one; the other is from
pooled data where CNVs are detected as diﬀerence of read counts from the average
depth of coverage (DOC) proﬁle in a region [185]. The raw data should therefore
be reanalysed including the use of programs like exome2CNV or PropSeg in order
to identify CNVs from the exome sequencing data, which is cheaper and faster than
additional usage of the array CGH technology [186], [187].
5.8.3. Whole Genome Sequencing or Target Sequencing of the Disease
Locus
When whole-exome sequencing fails to identify disease-causing variants one possible
explanation is that the mutation is located in an area of the genome which is not
targeted. Intronic as well as promoter regions are conceivable locations where genetic
changes could result in a disease phenotype as discussed in chapter 5.2 on page 51.
Therefore, it is a reasonable step to perform whole genome sequencing next in order
to identify the mutation causing OPDM. Alternatively, target resequencing for the
deﬁned disease locus on chromosome 10 could be done, which might be cheaper
and should provide a higher sensitivity since a recent study showed, that target
sequencing of genes associated with neuromuscular disorders resulted in 20-30%
more detected variants compared to whole exome sequencing [143]. Apart from
coverage of intronic as well as intergenic regions, WGS comprehends the advantages
of reliable detection of copy number variations as well as better identiﬁcation of
repeat expansions compared to WES [188]. However, variant detection from whole
genome sequencing is still limited by the ability to annotate and interpret non-
coding sequence variants. Additionally, there are only few data sets of high coverage
reference genomes to compare results to [37]. In the worst case one would identify
a large number of small genetic variants within the disease locus and would not be
able to ﬁnd the one true disease causing mutation. Still, whole-genome sequencing
is the most obvious next step in order to identify the genetic cause of OPDM.
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5.8.4. RNA-Sequencing
RNA-seq (RNA-sequencing), also called whole transcriptome shotgun sequencing
(WTSS) is a method to sequence the set of all messenger RNA in a population
of cells. Apart from being capable of detecting mutations, it comprises a number
of advantages over DNA sequencing: First, it is able to identify alternative spliced
transcripts, especially, when a cryptic splice acceptor site is missed by WES. Second,
it can detect gene fusions, which is more important in cancer research, but might be
underlying an inherited disease like OPDM. And third, it is widely used to analyse
gene expression which might be aﬀected by mutations in regulatory elements such
as the promoter [189]. If WES and WGS fail to detect good candidate variants, this
technology could be used to study the diﬀerences in gene expression with special
focus on those located within the deﬁned disease locus on chromosome 10 and on
chromosome 2 between patient derived material and control samples. However, this
would require either muscle tissue from a biopsy or ﬁbroblasts from a skin biopsy
which could be transformed into myoblasts by MyoD virus transduction [190]. This
would be challenging, as patients live in Turkey and also because invasively taking
tissue samples for research reasons rises ethical questions.
5.8.5. Immunohistochemical Staining for Candidate Gene Products
A possibility to get around the issue of taking further tissue samples would be
immunohistochemical studies of paraﬃn embedded tissue at hand. As there are
only 14 protein coding genes in the mapped disease locus on chromosome 10, im-
munohistochemical staining for their encoded proteins could identify aberrant stain-
ing patterns as well as reduced or missing transcription. The human protein at-
las (http://www.proteinatlas.org) summarises information on tissue expression,
sub-cellular localisation and provides antibodies for most known protein coding gene
products [98]. For all 14 proteins mentioned above, there are antibodies available
and could be used for further studies.
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Oculopharyngodistal myopathy (OPDM) is an inherited adult onset muscle disease
with both dominant and recessive patterns of inheritance. Ptosis is usually the initial
symptom, followed by distal weakness and swallowing diﬃculties. Histopathological
ﬁndings include chronic myopathic changes and rimmed vacuoles. Despite all eﬀorts,
the underlying genetic cause for OPDM could not yet be identiﬁed.
The aim of the study described in this thesis was to identify the mutation respon-
sible for OPDM and is based on 49 individuals from unrelated Turkish families as
well as three sporadic patients from England, Finland and Canada.
Linkage analysis was done using SNP-genotyping array data and showed high
LOD-scores for regions on chromosome 2 for a recessive family and on chromosome
10 for a large dominant family. To further map the disease loci ﬁnemapping was
carried out by microsatellite analysis. Two separate disease loci could be identiﬁed
and reconstruction of recombinant haplotypes mapped them to chr2 q14.2-q22.1 for
the recessive family and chr10 q22.3-q23.1 for the dominant family.
Subsequently, whole exome sequencing and Sanger sequencing of ﬁve individuals
from two unrelated families as well as three sporadic patients was used in order to
identify the underlying genetic cause of OPDM. Intriguingly, no likely disease caus-
ing variants or candidate genes could be identiﬁed in the Turkish families. However,
in one sporadic patient, a heterozygous variant in the MATR3 gene was identiﬁed,
which is predicted to cause the substitution of a conserved amino acid as well as
result in aberrant splicing. Another variant in MATR3, detected in 5 unrelated
families, has previously been associated with vocal cord pharyngeal distal myopa-
thy. This ﬁnding could replicate the association of MATR3 with a myopathy and
expand the phenotypical presentation of patients with MATR3 -related disorders.
It has been discussed that there is a number of possible explanations why the
underlying genetic cause of OPDM has remained elusive despite WES analysis in-
cluding the possibilities of larger deletions or duplications, intronic or intergenetic
mutations and also repeat expansions. There are also a number of problems arising
from the sequencing process and the bioinformatical analysis. Any of these issues
may be the reason, why the underlying genetic cause for OPDM has not yet been
identiﬁed and further studies including technologies like RNA-Seq or whole genome
sequencing will be necessary to ﬁnally understand the genetic basis of OPDM.
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7. Zusammenfassung
Die Oculopharyngodistale Myopathie (OPDM) ist eine erbliche Muskelerkrankung
des Jungend- und Erwachsenenalters, die sowohl autosomal dominant als auch rezes-
siv vererbt werden kann. Typischerweise entwickeln Patienten initial eine Ptose,
die von einer distalen Gliedergürtelschwäche und einer Dysphagie gefolgt wird.
Histopathologisch lassen sich chronische myopathische Veränderungen und vakuoläre
Einschlüsse nachweisen. Trotz intensiver Bemühungen konnte die genetische Ursache
der OPDM noch nicht identiﬁziert werden.
Das Ziel dieser Arbeit war es, die genetische Veränderung, die für die OPDM
verantwortlich ist zu ﬁnden und zu erforschen. Die Studie basierte auf 49 Indi-
viduen aus 9 nicht-verwandten türkischen Familien und sporadischen Patienten aus
England, Finnland und Kanada.
Mittels SNP-Array wurde eine Kopplungsanalyse durchgeführt, die hohe LOD-
Scores für Marker auf Chromosom 2 für eine Familie mit rezessivem und auf Chro-
mosom 10 für eine Familie mit dominantem Erbang ergab. Um den Genlokus für die
OPDM weiter einzugrenzen, wurde eine Untersuchung von Mikrosatelliten durchge-
führt, um die Haplotypen in den gekoppelten Regionen zu rekonstruieren. Hier
konnten zwei unterschiedliche Krankeitslozi identiﬁziert werden, Chromosom 2q14.2-
q22.1 für die rezessive und Chromosom 10q22.3-q23.1 für die dominante Familie.
Anschließend wurde von fünf betroﬀenen Individuen aus zwei nicht-verwandten
und von drei sporadischen Patienten eine Exom-Sequenzierung durchgeführt, um die
der Erkrankung zugrunde liegenden genetische Ursache zu identiﬁzieren. Zu unserem
Erstaunen konnten wir in den türksichen Familien keinerlei genetische Veränderun-
gen identiﬁzieren, die möglicherweise mit der Erkrankung assoziiert werden können.
Dennoch fand sich bei einem sporadischem Patienten eine heterozygote Variante
im MATR3 -Gen. Auf Grund der Variante wird der Austausch einer konservierten
Aminosäure und aberrantes Spleißen vorhergesagt. In 5 nicht-verwandten Familien
mit einer Stimmband-Pharyngealen distalen Myopathie konnte eine Mutation im
MATR3 -Gen als genetische Ursache identiﬁziert werden. Dieses Ergebnis könnte
eine Replikation der Assoziation von MATR3-Varianten mit Myopathien darstellen
und das phänotypische Spektrum dieser Erkrankungsgruppe erweitern.
Es wurde diskutiert, dass es eine Reihe möglicher Erklärungen gibt, weshalb
der, der OPDM zugrundeliegende, genetische Defekt bisher noch nicht identiﬁziert
75
7. Zusammenfassung
werden konnte, trotz der Sequenzierung des gesamten Exoms. Beispielsweise könn-
ten Deletionen oder Duplikationen, intronische oder intergene Mutationen und
auch Repeat-Expansionen eine Erkrankung hervorrufen. Es gibt außerdem einige
Schwierigkeiten beim Sequenzieren und bei der bioinformatischen Auswertung,
die bedacht werden müssen. All diese Punkte könnten ein Grund sein, weshalb
die genetische Ursache der OPDM bisher noch nicht identiﬁziert worden ist und
Folgestudien mit weitergehenden Methoden wie der Transkriptom- und Genomse-
quenzierung sind nötig, um den komplexen genetischen Mechanismus zu verstehen,
der für die OPDM verantwortlich ist.
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A.1. List of Primers
List of primers used:
MYPN :
Oligo Name Sequence (5'->3') Tm [◦C] MW [g/mol]
MYPN ex 18 fwd agcctgggtgacagagcaagac 64 6818
MYPN ex 18 rev ccagactcaaatagcagcagac 60,3 6706
MYPN ex18 fwd2 ctcagccaaagaggtgaagaa 57,9 6497
MYPN ex1 fwd cataggtgctgtcctgctatgg 62,1 6957
MYPN ex1 rev tgccctgttatcaaaacacact 56,5 6638
MYPN ex2 fwd tgggtgacaaagtgagaccttc 60,3 6799
MYPN ex2 rev ataaactggagctgttttcctg 58,4 6765
MYPN ex3 fwd atggtttgaatactgccaactc 56,5 6709
MYPN ex3 rev agaagagcgcatggtagaggag 62,1 6922
MYPN ex4 fwd aaatcttatgtcgtgtttaggaacc 58,1 7670
MYPN ex4 rev ggagccacccttcttaagttc 59,8 6357
MYPN ex5 fwd cacctgtaagcagtgatgcc 59,4 6101
MYPN ex5 rev tgcaagatggtcatggtcac 57,3 6157
MYPN ex6 fwd ttgggatgcatttcatat 54 6411
MYPN ex6 rev ccgtacatacagaagaccaaatc 58,9 6994
MYPN ex7 fwd atgcacatccacagaactgaag 58,4 6721
MYPN ex7 rev tggaaaggtgttcattaaatgttg 55,9 7461
MYPN ex8 fwd aatatccatcctgtccctgttg 58,4 6636
MYPN ex8 rev tgctggaattacagacatgagc 58,4 6783
MYPN ex9 fwd aattgttttgaccaattgttttc 51,7 7009
MYPN ex9 rev ttttagaagagccaagccagc 57,9 6439
MYPN ex10 fwd tgtgaacactttcccatttgtg 56,5 6691
MYPN ex10 rev gtgtgagcaactgtgcctagc 61,8 6462
MYPN ex11 fwd tctgaacattgtttgaaaggtg 54,7 6804
MYPN ex11 rev gagatttggtttgcacagagg 57,9 6541
MYPN ex12 fwd tgtcatttcaaccactctgatttc 57,6 7228
MYPN ex12 rev gtatccgaggactgaatcaagt 60,3 6768
MYPN ex13 fwd gcttcctcaattgtactgatgg 58,4 6716
MYPN ex13 rev agaccttcttgaaggcactg 57,3 6116
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MYPN ex14 fwd tcacttaaaagatggcagttgg 56,5 6798
MYPN ex14 rev tttcctcagcaatccttagtaactc 59,7 7526
MYPN ex15 fwd atttcacggtgttctggtcc 57,3 6089
MYPN ex15 rev atccagtactttggtgctcacg 60,3 6701
MYPN ex16 fwd tgttttacatcagctccacacc 58,4 6605
MYPN ex16 rev tgacattaaatactccaaacaagcc 58,1 7586
MYPN ex17 fwd agcaaggataaagaattcagcc 56,5 6785
MYPN ex17 rev atgaaggaattctggcagagg 57,9 6559
MYPN ex19 fwd ttcctggaaccctaaatttgac 56,5 6669
MYPN ex19 rev accttgcctgacccatttatc 57,9 6292
MYPN ex20 fwd gtgaaggacagaatgcacctc 59,4 6151
MYPN ex20 rev gcttggaaaccaccaagtctg 59,8 6415
MYPN ex11b fwd cgaagtatttcttcccctccac 60,3 6581
MYPN ex11b rev gagagccctgtttcagatcaag 60,3 6759
MYPN ex2b fwd ataaccctcgaagtcccacc 59,4 5990
MYPN ex2b rev aaaccaggtgcttaaatgataatac 56,4 7682
MYPN ex3 fwd (2) ttaagagaatatctggagctgtct 57,6 7406
MYPN ex3 rev (2) tgctgtatcctcattgcctaga 58,4 6676
MYPN ex2a fwd (2) ttgagctttaatttctaacgagtc 55,9 7332
MYPN ex9 fwd (2) gccagctttttatattgactttg 55,3 7010
MYPN ex9 rev (2) ggaatggaaacacaaaatctgc 56,5 6785
MYPN ex8 fwd (2) taatatccatcctgtccctgtt 56,5 6611
MYPN ex8 rev (2) tttattcatctcagtgtaacttcatt 55,3 7876
MYPN ex18 fwd (3) agaatgacccttctcttgctca 60,4
6645 MYPN ex16 fwd (2) gttctctaggtctgtagccatgc 62,4 7021
Table A.1.: List of Primers MYPN
POLR3A:
Oligo Name Sequence (5'->3') Tm [◦C] MW [g/mol]
POLR3A ex19 fwd ttagctcccagctgccaaag 59,4 6061
POLR3A ex19 rev attacagctcatgtgcaaaacg 56,5 6727
POLR3A ex1 fwd gcgagtagcggaagaggaag 61,4 6305
POLR3A ex1 rev atctctgaccctgcaagacc 59,4 6021
POLR3A ex2 fwd aggttggttatggtgggcta 57,3 6259
POLR3A ex2 rev gctcctttcaatctggtaagtca 58,9 6989
POLR3A ex3 fwd gcaaaagaaatgattctgtgtca 55,3 7095
POLR3A ex3 rev ctagatgtatcccccaccactc 62,1 6575
POLR3A ex4 fwd tcacgtggttaagggtacaaaa 56,5 6807
POLR3A ex4 rev aaaagctgactcccgaacatta 56,5 6696
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POLR3A ex5 fwd ggacctctcatctttcattgct 58,4 6627
POLR3A ex5 rev ttttggaagaaagtgggtgtct 56,5 6860
POLR3A ex6 fwd aaacatagtgaaggaaaaccttgc 57,6 7402
POLR3A ex6 rev tttttctcacattttcttgacca 53,5 6905
POLR3A ex7 fwd gcctcccatttccttgtaagtt 58,4 6627
POLR3A ex7 rev gagaagctggacagacactcct 32,1 6753
POLR3A ex8 fwd agtctctccgttcttattgttcc 58,9 6922
POLR3A ex8 rev tttctactgcctgttgtttgc 55,9 6360
POLR3A ex9 fwd caggatgcctctctttctccta 60,3 6612
POLR3A ex9 rev tgtggctgagtatgaccacagt 60,3 6790
POLR3A ex10 fwd tcctgatctgaagagggagaaa 58,4 6832
POLR3A ex10 rev agaagtccactgtttagcactga 58,9 7047
POLR3A ex11 fwd ttttaatgtttcaaaacagagaagc 54,8 7688
POLR3A ex11 rev tggtgttttcatgtaagtttcctt 55,9 7345
POLR3A ex12 fwd aaaccttgtgattcaggctttg 56,5 6740
POLR3A ex12 rev tgaatcactatgaacgaggaaca 57,1 7089
POLR3A ex13 fwd tgttggtcatggttcaaatttat 53,5 7074
POLR3A ex13 rev cactcatttcaccagtctaccc 60,3 6550
POLR3A ex14 fwd ggggtagactggtgaaatgagt 60,3 6919
POLR3A ex14 rev cagaaacaatgaatttgcttgc 54,7 6742
POLR3A ex15 fwd gctttgaggagaatttctgtttg 57,1 7115
POLR3A ex15 rev gggatgaaatggcagtaaaaga 56,5 6905
POLR3A ex16 fwd gcaggcataaactgtatttagtagg 59,7 7745
POLR3A ex16 rev tacctctattcatggctcagca 58,4 6645
POLR3A ex17 fwd gcatcttgcctcagtattttca 56,5 6651
POLR3A ex17 rev gctgtgactatcacattttctgg 58,9 7020
POLR3A ex18 fwd ctgttttacccttccaatctgc 58,4 6587
POLR3A ex18 rev ccaacggtctttgatctgaata 56,5 6709
POLR3A ex19 fwd tttctgatttgcgtggatttca 52,8 6761
POLR3A ex19 rev tgtgcaaaacgtgtactcaatac 57,1 7071
POLR3A ex20 fwd tgcttgtaaccttgagactcttg 58,9 7020
POLR3A ex20 rev aactgcaattgatagtccaaaca 55,3 7024
POLR3A ex21 fwd gctaaaagctcaccttgggtaa 58,4 6743
POLR3A ex21 rev cccttgcaaacagagttcaa 57,9 6381
POLR3A ex22 fwd cagtatccagattgggtccttt 58,4 6716
POLR3A ex22 rev tgtacacatggggaaacagaag 58,4 6841
POLR3A ex23 fwd gctgggactcacatcctaattt 58,4 6685
POLR3A ex23 rev ccagggagcacaaaactcttta 58,4 6712
POLR3A ex24 fwd ggtgataaccagaagcctctcc 62,1 6704
POLR3A ex24 rev atgccacccagagtttaagaca 58,4 6712
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POLR3A ex25 fwd cacttgggtttaacaaagcagta 57,1 7071
POLR3A ex25 rev tggcagctgatttttacacttc 56,5 6691
POLR3A ex26 fwd aagcagtcgtgtgctcttagg 59,8 6477
POLR3A ex26 rev tgcttagctcttgccctagttt 58,4 6658
POLR3A ex27 fwd gggtgcttagaacaaacctgac 60,3 6768
POLR3A ex27 rev gggataaggccaagaagaaatta 57,1 7178
POLR3A ex28 fwd agctggggtgatcaaggtga 59,4 6262
POLR3A ex28 rev tgcagatggcacaaggaaga 57,3 6224
POLR3A ex29 fwd acagggtttgctttgaaactg 55,9 6476
POLR3A ex29 rev tctatgatggtcctcacagcag 60,3 6710
POLR3A ex30 fwd ggaggatttttgttgattgtattg 55,9 7474
POLR3A ex30 rev gcctagccatggtctatttgta 58,4 6716
Table A.2.: List of Primers POLR3A
Microsatellites:
Oligo Name Sequence (5'->3') Tm [◦C] MW [g/mol]
D10S606 fwd tttgaacctgggagacg 52,8 5250
D10S606 rev catggacattctgctgc 52,8 5161
D10S1136 fwd gtgggctgaaactctgctt 56,7 5834
D10S1136 rev gtggggaaacagacaaacc 56,7 5879
D10S1730 fwd gtgcagccactgttgagag 58,8 5868
D10S1730 rev aagtttgagaaccactggtctatc 59,3 7351
D10S1164 fwd ggtgctgaggtgggaagat 58,8 5988
D10S1164 rev gaggtgtaaggaaagcacga 57,3 6264
D10S201 fwd agctcatgggatggaagcat 57,3 6206
D10S201 rev agctaaaaggctgctggaga 57,3 6215
D10S1774 fwd ctcttgtccacttggcctca 59,4 5994
D10S1774 rev cctgccttcacactgctctg 61,4 5979
D10S523 fwd tggaggttgtggtgagctg 58,8 5970
D10S523 rev ccattctagactgcggctg 58,8 5779
D10S583 fwd tctgaccaaaataccaaaagaac 55,3 7002
D10S583 rev agagactccagatgtttgatga 56,5 6798
D10S577 fwd ttgcacaccagcctaag 52,8 5139
D10S577 rev gcccaagagttggagac 55,2 5244
Table A.3.: List of Primers Microsatellites
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UNC5B
Oligo Name Sequence (5'->3') Tm [◦C] MW [g/mol]
UNC5B ex9 fwd gctcagactggaactcagcac 61,8 6400
UNC5B ex9 rev ctctggtctgggtaccacca 61,4 6068
Table A.4.: List of Primers UNC5B
NRG3
Oligo Name Sequence (5'->3') Tm [◦C] MW [g/mol]
NRG3 ex1-1 fwd cagggagcggatttgcat 56,0 5579
NRG3 ex1-1 rev atgaagccgatgaacagaggta 58,4 6841
NRG3 ex1-2 fwd ggctcctaggatgagtgaagg 61,8 6551
NRG3 ex1-2 rev aagtggtagtggtggtggtctc 62,1 6877
NRG3 ex1-3 fwd ctcagcctcatgcttctcaaat 58,4 6605
NRG3 ex1-3 rev agcgtgctgctactgaagaac 59,8 6455
NRG3 ex1-4 fwd caccaccactaccacttccac 60,8 6200
NRG3 ex1-4 rev ggaggaggaagaagaggaagaa 60,3 7004
NRG3 ex1-5 fwd ggcatacgctacctcctccta 61,8 6302
NRG3 ex1-5 rev agggggcttgctagaaaacag 59,8 6544
NRG3 ex1-1 fwd (2) cggctcctaggatgagtgaag 61,8 6511
NRG3 ex1-1 rev (2) gaacagaggtaccacgcacag 61,8 6458
NRG3 ex1-2 fwd (2) tgaagccgatgaacagaggta 57,9 6528
NRG3 ex1-2 rev (2) atgaagccgatgaacagaggt 57,9 6528
NRG3 ex1-3 fwd (2) aagaccggctcctaggatgagt 62,1 6784
NRG3 ex1-3 rev (2) aaggtgaagaccggctccta 59,4 6151
NRG3 ex2 fwd cattttcccaggaggtgtttag 58,4 6756
NRG3 ex2 rev ctgagggccctgtcaataatg 59,8 6406
NRG3 ex2 fwd (2) gagggttggagctgtctgtcta 62,1 6837
NRG3 ex2 rev (2) aaacggtgggactgtgtgtatc 60,3 6830
NRG3 ex1-1 fwd (3) tcttccgagctccttaccg 58,8 5690
NRG3 ex1-1 rev (3) agaggaagaaggggtcctg 58,8 5966
NRG3 ex1-1 fwd (4) ccctcttccgagctccttac 61,4 5939
NRG3 ex1-1 rev (4) atgtaagccgatgaacagaggta 58,4 6841
NRG3 ex2 fwd (2) agcagtcatttttgagagcaca 56,5 6758
NRG3 ex2 rev (2) cagatttttcccctcttttcct 56,5 6553
NRG3 ex9 fwd ggccacaacaagtctactgga 59,8 6424
NRG3 ex9 rev tcactgaattctcacagcaacc 58,4 6623
Table A.5.: List of Primers NRG3
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Micro RNAs
Oligo Name Sequence (5'->3') Tm [◦C] MW [g/mol]
MIR_554 fwd tcaaaaatgaaaatatgctggatg 54,2 7432
MIR_554 rev tttaacagttcccatgcacttg 56,5 6660
hsa-miR-3198-3p fwd tggccctagaattgtaatccat 56,5 6709
hsa-miR-3198-3p rev actcccccataaacctgaaagt 58,4 6632
Table A.6.: List of Primers miRNAs
RPS24
Oligo Name Sequence (5'->3') Tm [◦C] MW [g/mol]
RPS24 fwd gggctgtggcaagtatttacag 60,3 6830
RPS24 rev ggagaagaaggtggagagatga 60,3 6986
Table A.7.: List of Primers RPS24
ZMIZ1
Oligo Name Sequence (5'->3') Tm [◦C] MW [g/mol]
ZMIZ1 3'-UTR fwd gttccttttcactgtctgtgg 57,9 6385
ZMIZ1 3'-UTR fwd (2) gggcgagttgattcacttactc 60,3 6741
ZMIZ1 3'-UTR rev gggacactttaagggaaaaacc 58,4 6801
ZMIZ1 ex9 fwd ctatggccaatgccaacaac 57,3 6054
ZMIZ1 ex9 rev actgctgcagcgccttatct 59,4 6043
ZMIZ1 ex10 fwd caagtggcacaaatgaatgg 55,3 6199
ZMIZ1 ex10 rev caccctaatgcagtcagctctc 62,1 6615
ZMIZ1 ex11 fwd tccctccctgcactttcaat 57,3 5938
ZMIZ1 ex11 rev acacctcctcaagtccctcaag 62,1 6584
ZMIZ1 ex12 fwd gtgacctggctatgtgacgtt 59,8 6468
ZMIZ1 ex12 rev aacacacgcagggtcagagt 59,4 6160
ZMIZ1 ex21 fwd aggtcacctgggtgtctgtc 61,4 6139
ZMIZ1 ex21 rev gccaccatcagcacagaaat 57,3 6063
ZMIZ1 ex21 fwd (2) tgtggtgagagtgggagcag 61,4 6318
ZMIZ1 ex21 rev (2) gggggatgtgttacttctctct 60,3 6763
ZMIZ1 ex23 fwd ggttgtgttgggtttcattttc 56,5 6784
ZMIZ1 ex23 rev ctcacacccaccccttctct 61,4 5868
Table A.8.: List of Primers ZMIZ1
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PPIF
Oligo Name Sequence (5'->3') Tm [◦C] MW [g/mol]
PPIF ex1 fwd caggggtagtccacggacag 63,5 6192
PPIF ex1 rev cattctcagaaatggggaaact 56,5 6767
PPIF ex2 fwd ttggatgtttattgaccccttt 54,7 6697
PPIF ex2 rev aatgctgagacagcctacagtg 60,36 6768
Table A.9.: List of Primers PPIF
EIF5AL1
Oligo Name Sequence (5'->3') Tm [◦C] MW [g/mol]
EIF5AL1 ex1 fwd tcatatgaaagacgtgtaaaatgc 55,9 7408
EIF5AL1 ex1 rev acgaaggtcctctggtacctc 61,8 6382
EIF5AL1 ex1 fwd (2) gtgtaaaatgcctgggtagagg 60,3 6879
EIF5AL1 ex1 rev (2) cttgccaaggtctccctcag 61,4 6028
EIF5AL1 ex1 fwd (3) aagatcgtggagatgtctgctt 58,4 6805
EIF5AL1 ex1 rev (3) ggtggggaaaaccaaaataaaa 54,7 6858
Table A.10.: List of Primers EIF5AL1
C10orf57
Oligo Name Sequence (5'->3') Tm [◦C] MW [g/mol]
C10orf57 fwd gagactcgctctcagggactt 61,8 6098
C10orf57 rev gattgtgcttgcacgacttc 57,3 6446
Table A.11.: List of Primers C10orf57
PLAC9
Oligo Name Sequence (5'->3') Tm [◦C] MW [g/mol]
PLAC9 fwd ggttctctcgagccagaaagt 59,8 6446
PLAC9 rev cagctctctctccgtctctctc 64,0 6524
PLAC9 fwd (2) gctcgtaacaaacccctgac 59,4 6030
PLAC9 rev (2) cattccttcctcgccatct 56,7 5625
Table A.12.: List of Primers PLAC9
ANXA11
Oligo Name Sequence (5'->3') Tm [◦C] MW [g/mol]
ANXA11 ex11 fwd cccatctactgagccatgtgt 59,8 6357
ANXA11 ex11 rev caggctctgctttgtgtcct 59,4 6065
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Table A.13.: List of Primers ANXA11
SH2D4B
Oligo Name Sequence (5'->3') Tm [◦C] MW [g/mol]
SH2D4B ex1 fwd aactgacaatgctgcacagaga 58,4 6761
SH2D4B ex1 rev cctggccctgctaatttttct 57,9 6314
SH2D4B ex1 fwd (2) tgggtagaggagatgagttcgt 60,3 6910
SH2D4B ex1 rev (2) atcttgaagaagggcacagc 57,3 6175
SH2D4B ex4 fwd ggttcctggactattaggttgg 60,3 6812
SH2D4B ex4 rev ccaaactacacagcaaatctgg 58,4 6681
Table A.14.: List of Primers SH2D4B
AK302451
Oligo Name Sequence (5'->3') Tm [◦C] MW [g/mol]
AK302451 fwd gaactcaaacactccctccatc 60,3 6568
AK302451 rev tgaggagattcatgtgaaggtg 58,4 6894
Table A.15.: List of Primers AK302451
AX747983
Oligo Name Sequence (5'->3') Tm [◦C] MW [g/mol]
AX747983 ex1 fwd gacctctgttattccagcaacc 60,3 6630
AX747983 ex1 rev tgggtaatcaatcccctttatg 56,5 6700
AX747983 ex2 fwd aagatggctgtggaaactgatt 56,5 6838
AX747983 ex2 rev gaattcttggctgaactgtgtg 58,4 6796
AX747983 ex2 fwd (2) gaggatcagttgagtccaggag 62,1 6864
AX747983 ex2 rev (2) ggctgaactgtgtgcaatagaa 58,4 6823
Table A.16.: List of Primers AX747983
ZCCHC24
Oligo Name Sequence (5'->3') Tm [◦C] MW [g/mol]
ZCCHC24 ex1 fwd aggaagagcgggtcagacag 61,4 6629
ZCCHC24 ex1 rev aaaagtttcctgcccaactttc 56,6 5941
ZCCHC24 ex2 fwd agcagggacaaaagggtagag 59,8 6602
ZCCHC24 ex2 rev cccaaggcagaggctgtagtat 62,1 6784
ZCCHC24 ex2 fwd (2) atttgaactcaggcttctggag 58,4 6765
ZCCHC24 ex2 rev (2) aatcccagcagggacaaaag 57,3 6153
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ZCCHC24 ex4 fwd gcttttgcttgcctttgtcc 57,3 6031
ZCCHC24 ex4 rev ctctccctcactgtgtctgtca 62,1 6588
ZCCHC24 ex4 fwd (2) ctcatcgggtgtgtgtctctc 61,8 6395
ZCCHC24 ex4 rev (2) ctggacatgggcttttgctt 57,3 6129
Table A.17.: List of Primers ZCCHC24
FAM213A
Oligo Name Sequence (5'->3') Tm [◦C] MW [g/mol]
FAM213A ex1 fwd caaccagcaccatcttctcc 59,4 5941
FAM213A ex1 rev accagtatgcttgctctcattg 58,4 6676
FAM213A alternate ex fwd catctacttgggaggctgagg 61,8 6502
FAM213A alternate ex rev acccactgaaagagaagcagag 60,3 6795
FAM213A alternate ex fwd (2) cacgtgtagtcccatctacttg 60,3 6661
FAM213A alternate ex rev (2) tgaaagagaagcagagacacaga 58,9 7172
Table A.18.: List of Primers FAM123A
MAT1A
Oligo Name Sequence (5'->3') Tm [◦C] MW [g/mol]
MAT1A ex9 fwd gctgtgttacagttcgttgctc 60,3 6723
MAT1A ex9 rev tgacaggacaggctaaatgaga 58,4 6841
Table A.19.: List of Primers MAT1A
GHITM
Oligo Name Sequence (5'->3') Tm [◦C] MW [g/mol]
GHITM ex2 fwd tttggttggttttgccttttt 52,0 6421
GHITM ex2 rev aggagggaccagaatgatacaa 58,4 6850
Table A.20.: List of Primers GHITM
CDHR1
Oligo Name Sequence (5'->3') Tm [◦C] MW [g/mol]
CDHR1 ex1 fwd gagccgtgtcatcctcttagc 61,8 6373
CDHR1 ex1 rev aggaagatggaaggacttctcc 60,3 6808
CDHR1 alternate exon fwd gataaatggatggagctgctg 60,3 6821
CDHR1 alternate exon rev tggtgggtagggaagtattcag 60,3 6910
Table A.21.: List of Primers CDHR1
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LRIT2
Oligo Name Sequence (5'->3') Tm [◦C] MW [g/mol]
LRIT2 ex2 fwd gtttgagatccaagaccctcag 60,3 6719
LRIT2 ex2 rev tggccagatgttagagggttat 58,4 6845
LRIT2 ex3 fwd gataaatggatggagctgctg 57,9 6550
LRIT2 ex3 rev ccccggaatcaatacttatgct 58,4 6654
LRIT2 alternate exon fwd ctgacagagcagtgtcttctcc 62,1 6686
LRIT2 alternate exon rev ggcacttcctgaagctcataat 58,4 6694
Table A.22.: List of Primers LRIT2
LRIT1
Oligo Name Sequence (5'->3') Tm [◦C] MW [g/mol]
LRIT1 ex2 fwd gtgataacaggcagaactggag 60,3 6857
LRIT1 ex2 rev aagaccccaggtgaaggttg 59,4 6191
LRIT1 ex3 fwd cttcagccagcttgaactgag 59,8 6406
LRIT1 ex3 rev aagagccactgtcattgttgaa 56,5 6758
LRIT1 ex4 fwd ctgtgaacttggccctgaaag 59,8 6446
LRIT1 ex4 rev gtcagctcctcctttgtgct 59,4 6025
Table A.23.: List of Primers LRIT1
MYOT
Oligo Name Sequence (5'->3') Tm [◦C] MW [g/mol]
MYOT ex5 fwd gaacttaccagggctgttcaaa 58,4 6743
MYOT ex5 rev ttcccctgtgatagttttgatg 56,5 6722
Table A.24.: List of Primers MYOT
FKRP
Oligo Name Sequence (5'->3') Tm [◦C] MW [g/mol]
FKRP fwd ctctacgaggagcgctggac 63,5 6143
FKRP rev gtactgcacgcggaaaaagt 57,3 6175
Table A.25.: List of Primers FKRP
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RYR1
Oligo Name Sequence (5'->3') Tm [◦C] MW [g/mol]
RYR1 fwd tccctaagacccttagcttgttc 60,6 6925
RYR1 rev atgtgaaattgcctcactcctc 58,4 6645
RYR1 ex93 fwd gaatggttttgaatgaatgaactc 55,9 7430
RYR1 ex93 rev caaggtgagcaggagaggtg 61,4 6296
Table A.26.: List of Primers RYR1
Intronic repeats
Oligo Name Sequence (5'->3') Tm [◦C] MW [g/mol]
NRG3 repeat1 fwd gggcaaggagactcttctaggt 62,1 6815
NRG3 repeat1 rev tagcaattgaatgaaggaggag 56,5 6896
NRG3 repeat2 fwd agcttctttcttgttgtgagga 56,5 6762
NRG3 repeat2 rev gtggtggtgcatgtctgtagtc 62,1 6828
NRG3 repeat3 fwd tttatgtgctcttggattgctg 56,5 6753
NRG3 repeat3 rev caaataggagggatgtgcaagt 58,4 6872
NRG3 repeat4 fwd caaattgaaagtctgccatcct 56,5 6678
NRG3 repeat4 rev gtgtccaacccaagaaaatgat 56,5 6736
NRG3 repeat5 fwd aaggaaaatgacaggctgagaa 56,5 6874
NRG3 repeat5 rev tgtagtcccagctactcggaag 62,1 6735
LOC100132987 rep fwd gtcagggttctgcagctctaaa 60,3 6750
LOC100132987 rep rev ggcaacacagcaagatgtagtc 60,3 6777
ZMIZ1 rep fwd ccttggtcataagccctttgta 58,4 6676
ZMIZ1 rep rev ctctgcctaggaaaaccagaga 60,3 6737
LOC219347 rep fwd acctggatccaatgtacacaag 58,4 6632
LOC219347 rep rev tagccaaggtgagtcagtgaaa 58,4 6832
TSPAN14 rep fwd tttgagacagggtcttgctgt 57,9 6483
TSPAN14 rep rev ggtgaaaccccatctctacaaa 58,4 6672
Table A.27.: List of Primers Intronic repeats
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A.2. Merlin Input Files
A OPDM
M rs876724
M rs12714396
M rs381726
M rs300739
M rs1350779
M rs6548222
M rs907302
M rs1320362
M rs2293085
M rs7575263
M rs6548255
M rs7559853
M rs5020134
M rs7426276
M rs938326
M rs1368233
M rs709276
M rs1667023
M rs1729916
M rs6767
M rs12988769
M rs1024026
M rs10174999
M rs792065
M rs813779
M rs2118186
M rs1079417
M rs921229
M rs309276
M rs2352400
M rs7598142
M rs1560382
M rs1364054
M rs1025053
M rs3102960
M rs168293
M rs2001660
M rs12995394
M rs1309
M rs728282
M rs4669630
M rs1686430
M rs730990
M rs726843
M rs1370548
M rs6432244
M rs4668758
M rs1469217
M rs956596
M rs779343
M rs1510834
M rs765786
M rs1862110
M rs767624
M rs340767
Figure A.1.: Exemplary .dat Merlin input ﬁle. Left column indicates that all SNPs
are markers to be considered by the program. Right column lists the SNPs which have
been genotyped. Note, that only a few markers are shown to ﬁt this ﬁgure to one page.
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CHROMOSOME MARKER POSITION
2 rs876724 0,001765
2 rs12714396 0,002412
2 rs381726 0,0033
2 rs300739 0,00644
2 rs1350779 0,006729
2 rs6548222 0,137572
2 rs907302 0,427542
2 rs1320362 0,558847
2 rs2293085 0,767507
2 rs7575263 0,869165
2 rs6548255 0,939968
2 rs7559853 1,165881
2 rs5020134 1,208016
2 rs7426276 1,347943
2 rs938326 1,861933
2 rs1368233 2,657625
2 rs709276 4,87012
2 rs1667023 5,572099
2 rs1729916 6,740577
2 rs6767 10,90533
2 rs12988769 8,525858
2 rs1024026 9,285462
2 rs10174999 9,286284
2 rs792065 11,69467
2 rs813779 11,82321
2 rs2118186 11,93157
2 rs1079417 12,76831
2 rs921229 13,24073
2 rs309276 14,80846
2 rs2352400 14,80918
2 rs7598142 14,81039
2 rs1560382 14,86523
2 rs1364054 18,72203
2 rs1025053 18,77044
2 rs3102960 19,93544
2 rs168293 21,33897
2 rs2001660 22,32186
2 rs12995394 23,3701
2 rs1309 25,52654
2 rs728282 25,52657
2 rs4669630 25,52749
2 rs1686430 25,52749
2 rs730990 26,75621
2 rs726843 27,11846
2 rs1370548 27,96878
2 rs6432244 28,3712
2 rs4668758 29,83475
2 rs1469217 31,26161
2 rs956596 31,26445
2 rs779343 31,26473
2 rs1510834 32,54884
2 rs765786 32,73141
2 rs1862110 33,28779
2 rs767624 34,0628
2 rs340767 35,71467
Figure A.2.: Exemplary .map Merlin input ﬁle. This ﬁle connects all markers from
the .dat ﬁle to a position on a Chromosome in Centimorgan. Note, that only a few
markers are shown to ﬁt this ﬁgure to one page.
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1 1 0 0 1 2 X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X 
1 2 0 0 2 1 X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X 
1 5 0 0 2 0 X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X 
1 6 0 0 1 0 X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X 
1 7 0 0 2 0 X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X 
1 8 1 2 1 2 X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X 
1 9 6 5 1 2 X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X 
1 10 6 7 1 2 X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X 
1 11 0 0 2 1 X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X 
1 9401 0 0 2 1 X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X 
1 9402 8 9401 2 2 A/G A/G A/G G/G A/G A/C A/A A/C A/G G/G G/G G/G A/G A/G A/G A/A A/A A/C A/A G/G G/G G/G A/G A/G G/G C/C C/C A/G A/G G/G A/A A/A A/G A/G A/A A/A A/G A/A A/A A/A A/G A/G A/G A/G G/G A/A C/C G/G G/G A/A 
1 8898 8 9401 1 0 A/G A/G A/G G/G A/G A/C A/A A/C A/G G/G G/G G/G A/G A/G A/G A/A A/A A/C A/A G/G G/G G/G A/G A/G G/G C/C C/C G/G A/A G/G A/A A/A A/A A/G A/A A/A A/G A/A A/G A/G G/G G/G A/A A/G A/G A/G C/C A/A A/A G/G 
1 8863 1 2 2 0 A/G A/G A/G A/G A/G A/C G/G C/C G/G G/G A/A G/G A/A G/G G/G A/A A/A A/A G/G A/G A/A A/G G/G A/G A/G C/C C/C G/G A/A A/G A/A G/G G/G A/G A/A A/G A/G A/A A/A A/A G/G G/G A/A A/G A/G A/G C/C G/G G/G A/A 
1 8879 9 8863 2 2 A/G A/G G/G G/G A/G A/C A/G C/C G/G G/G A/A G/G A/A G/G G/G A/A A/A A/A A/G A/G A/G G/G G/G A/G A/G C/C C/C G/G A/G A/G A/G G/G G/G A/G A/G A/G G/G A/G A/A A/A G/G G/G A/G A/G G/G A/G A/C G/G G/G A/A 
1 8869 9 8863 2 2 A/G A/G G/G G/G A/G A/C A/G C/C G/G G/G A/A G/G A/A G/G G/G A/A A/A A/A A/G A/G A/G G/G G/G A/G A/G C/C C/C G/G A/G A/G A/G G/G G/G A/G A/G A/A A/G A/G A/A A/A G/G G/G A/G G/G A/G A/G A/C G/G G/G A/A 
1 8868 0 0 1 1 A/G A/A A/A G/G A/A A/A G/G A/C A/G A/G G/G A/G A/A G/G G/G A/A A/A C/C A/G A/G G/G A/G G/G G/G G/G C/C C/C A/G G/G A/A A/A A/G A/G A/G A/A A/G A/A A/G A/A A/A G/G G/G A/G A/G G/G A/A C/C G/G G/G A/A 
1 8866 8868 8869 1 0 A/A A/G A/G G/G A/G A/C G/G A/C A/G A/G A/G G/G A/A G/G G/G A/A A/A A/C G/G A/G A/G G/G G/G A/G A/G C/C C/C A/G A/G A/G A/A A/G A/G G/G A/A A/G A/A A/G A/A A/A G/G G/G A/G G/G A/G A/A C/C G/G G/G A/A 
1 8873 9 8863 2 2 A/A G/G G/G G/G G/G C/C A/G A/C G/G G/G A/G A/G A/G G/G A/G A/A A/A A/A G/G A/G A/A G/G A/G A/A A/G C/C C/C G/G A/G A/G A/A G/G G/G A/G A/G A/G A/G A/G A/A A/A A/G A/G A/A A/A G/G A/G C/C G/G G/G A/A 
1 9405 6 7 1 2 G/G A/A A/G G/G A/A A/A A/G A/C G/G G/G A/G A/G A/A G/G G/G X/X A/A A/C A/A A/G A/G G/G A/G G/G A/G C/C C/C A/G G/G A/A A/G G/G G/G A/A G/G A/G A/G G/G A/G A/G A/G A/G A/G A/G G/G G/G A/C G/G A/G A/G 
1 9403 10 11 1 2 A/G A/G A/G G/G A/G A/C A/A A/C G/G G/G G/G A/A G/G G/G A/A A/A A/A A/A G/G A/G A/A G/G A/G A/G G/G C/C C/C G/G A/G A/G A/A G/G A/G G/G A/G A/G G/G A/G A/G A/G A/A A/A G/G A/A A/G A/G C/C G/G A/G A/G 
1 8801 10 11 1 2 G/G A/A A/A G/G A/A A/A A/A A/C G/G G/G G/G A/A G/G G/G A/A A/A A/A A/A G/G A/G A/A G/G A/G A/G G/G C/C C/C G/G A/G A/G A/A G/G A/G G/G A/G A/G G/G A/G A/G A/G A/A A/A G/G A/A A/G A/G C/C G/G A/G A/G 
1 8892 6 7 1 2 A/G A/G A/G G/G A/G A/C A/G A/C A/G G/G A/G A/A G/G G/G A/G A/G A/A A/A A/G A/G A/G G/G A/G A/A G/G C/C A/C G/G A/G A/G A/A G/G A/G G/G A/A A/G A/G A/A A/A A/A A/G A/G G/G A/A G/G A/A C/C A/G A/G A/G 
1 8893 0 0 2 1 X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X 
1 8870 8892 8893 1 2 G/G A/A A/A G/G A/A A/A G/G A/C A/A A/G A/G A/A A/G G/G G/G A/G A/A A/A A/A A/A G/G G/G G/G A/A G/G C/C A/C A/G A/G A/G A/A A/G A/G A/G A/A A/G A/G A/A A/A A/A G/G G/G A/G A/G A/G A/A C/C A/G A/G A/G 
2 1 0 0 1 2 X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X 
2 2 0 0 2 1 X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X 
2 3 0 0 2 1 X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X 
2 8876 1 2 1 2 G/G A/A A/A A/A A/A A/A A/A C/C A/G A/G A/G G/G A/G G/G A/G A/A A/G C/C A/G A/A A/G A/G G/G G/G A/G C/C C/C A/G G/G A/A A/A A/G A/G A/G A/G A/G A/G A/G A/G A/G G/G G/G A/G G/G A/G A/G A/A G/G G/G A/A 
2 8875 1 2 1 2 G/G A/A A/A A/A A/A A/A A/A C/C A/G A/G A/G G/G A/G G/G A/G A/A A/G C/C A/G A/A A/G A/G G/G G/G A/G C/C C/C A/G G/G A/A A/A A/G A/G A/G A/G A/G A/G G/G A/A A/A A/G A/G A/A A/G G/G G/G A/C A/G A/G A/G 
2 8878 1 3 2 2 A/G A/G G/G G/G A/G A/C A/G A/C G/G A/G G/G G/G A/A G/G A/G A/G A/A A/C G/G A/G G/G A/G A/G A/G G/G C/C C/C G/G A/A G/G A/A A/G G/G A/G A/G G/G A/G A/G A/G A/G G/G G/G G/G G/G A/A A/A A/C G/G G/G A/A 
3 1 0 0 1 2 X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X 
3 2 0 0 2 1 X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X 
3 8887 1 2 2 2 G/G A/A A/G G/G A/A A/A A/A C/C G/G A/G A/A G/G A/A G/G A/G A/A A/A A/C G/G A/A G/G G/G G/G G/G G/G C/C A/C G/G A/A G/G A/G A/A A/G A/G A/G A/G A/A G/G A/G A/G G/G G/G A/G A/G G/G A/A A/C A/A A/A G/G 
3 8855 1 2 1 2 G/G A/A A/A A/G A/A A/C A/G C/C A/G A/G A/G A/G A/G G/G A/G A/G G/G C/C A/A G/G G/G A/A G/G G/G G/G C/C C/C G/G A/G A/G A/A A/A A/G A/G A/G A/A A/G A/A A/A A/A G/G G/G A/A G/G G/G A/G A/C A/A A/A G/G 
3 8888 1 2 2 2 G/G A/A A/G G/G A/A A/A A/G C/C A/G A/A A/G A/G A/G G/G A/G A/G A/G A/C A/G A/G G/G A/G G/G G/G G/G C/C A/C G/G A/G A/G A/A A/A A/G A/G A/A A/A A/A A/G A/G A/G G/G G/G A/A A/G G/G A/A A/C A/A A/A G/G 
3 8852 1 2 2 2 G/G A/A A/G G/G A/A A/A A/A C/C G/G A/G A/A G/G A/A G/G A/G A/A A/A A/C G/G A/A G/G G/G G/G G/G G/G C/C A/C G/G A/A G/G A/G A/A A/G A/G A/G A/G A/A G/G A/G A/G G/G G/G A/G A/G G/G A/A A/C A/A A/A G/G 
3 8854 1 2 1 2 G/G A/A A/G G/G A/A A/A A/G C/C A/G A/A A/G A/G A/G G/G A/G A/G A/G A/C A/G A/G G/G A/G G/G G/G G/G C/C A/C G/G A/G A/G A/A A/A A/G A/G A/A A/A A/A A/G A/G A/G G/G G/G A/A A/G G/G A/A A/C A/A A/A G/G 
4 1 0 0 2 0 X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X 
4 2 0 0 1 0 X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X 
4 3 0 0 1 1 X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X X/X 
4 8811 1 2 2 1 A/G A/G G/G G/G A/G A/C A/A A/C A/G A/G G/G G/G A/A G/G A/G A/G A/A C/C A/G A/G G/G A/A G/G A/G G/G A/C C/C A/A A/A G/G A/G A/G A/G A/G A/A A/A A/G A/A A/A A/A A/G A/G A/G A/A A/G A/A C/C A/G A/G A/G 
4 8810 1 2 2 2 A/A G/G G/G G/G G/G C/C A/G A/A A/G G/G A/G A/G A/A G/G A/G A/G A/G C/C G/G A/G G/G A/A G/G A/G G/G C/C A/C A/G A/G A/G A/G A/G A/A A/G A/A A/G G/G A/A A/G A/G A/G A/G A/A G/G G/G A/G C/C A/G A/A G/G 
4 8871 1 2 1 2 A/A G/G G/G G/G G/G C/C G/G A/C A/A G/G A/G A/A A/A G/G G/G A/A A/G A/C G/G A/G G/G A/A G/G G/G A/G C/C A/A G/G G/G A/A G/G G/G A/A A/A A/A A/G G/G A/A A/G A/G A/G A/G A/A G/G G/G A/G C/C A/G A/A G/G 
4 8872 8811 3 1 2 A/G A/G A/G G/G A/G A/C A/G A/A A/G A/G G/G G/G A/A G/G A/A A/G A/A C/C G/G A/G A/G A/A G/G A/A G/G C/C C/C A/A A/G A/G A/A A/G A/G A/G A/A A/G G/G A/A A/G A/G G/G G/G A/G A/G A/G A/G C/C A/G A/G A/G 
Figure A.3.: Exemplary .ped Merlin input ﬁle. First column names the family, second
column the individual's name. Since the program requires a consistent pedigree, parents
which have not been genotyped have to be added and numbered. Third column names
the father and fourth column the mother of each individual giving the program all
the information to reconstruct the pedigree. Fifth column indicates disease status, 1
stands for unaﬀected, 2 for aﬀected and 0 for unknown. Then, SNP data is added
after each individual according to the order of SNPs in the .map ﬁle. If a family member
has not been genotyped X/X is used.
106
A. Anhang
OPDM 0,01 0.01,0.99,0.99 Dominant_Model
OPDM 0,01 0.01,0.01,0.99 Recessive_Model
OPDM 0,01 0.01,0.5,0.99 Co-Dominant_Model
Figure A.4.: Exemplary .model Merlin input ﬁle. This ﬁle is required for parametric
linkage analysis and consists of 4 ﬁelds per line: an aﬀection status label (matching the
data ﬁle), a disease allele frequency, a probability of being aﬀected for individuals with
0, 1 and 2 copies of the disease allele (penetrances), and ﬁnally a label for the analysis
model.
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A.3. List of homozygous variants shared by OPDM3,
OPDM4 and OPDM5
Chr Position Ref Obs Variant Func
chr1 109792750 - CGC CELSR2:c.49_50insCGC:p.L17delinsPL exonic
chr1 31905904 - CAG
SERINC2:c.1116_1117insCAG:
p.Q372delinsQQ
exonic
chr10 7605079 C - ITIH5:c.2154delG:p.M718fs exonic
chr10 97920100 - C ZNF518A:c.4021_4022insC:p.L1341fs exonic
chr11 111853108 - C DIXDC1:c.181_182insC:p.L61fs exonic
chr11 118898437 C - SLC37A4:c.527delG:p.W176fs exonic
chr11 118939941 - C VPS11:c.222_223insC:p.S74fs exonic
chr11 125452303 - C EI24:c.735_736insC:p.P245fs exonic
chr11 14101494 - C SPON1:c.602_603insC:p.A201fs exonic
chr11 3661588 - TGG ART5:c.71_72insCCA:p.P24delinsPT exonic
chr11 67786065 - C ALDH3B1:c.231_232insC:p.N77fs exonic
chr11 67795380 - C ALDH3B1:c.1268_1269insC:p.P423fs exonic
chr11 76751543 T - B3GNT6:c.948delT:p.L316fs exonic
chr11 76751605 T - B3GNT6:c.1010delT:p.L337fs exonic
chr12 124824739 - GCCGCTGCT
NCOR2:c.5470_5471insAGCAGCGGC:
p.S1824delinsSSGS
exonic
chr12 6777111 CTG - ZNF384:c.1153_1155del:p.385_385del exonic
chr12 6938024 - G P3H3:c.419_420insG:p.R140fs exonic
chr12 7080212 - C EMG1:c.126_127insC:p.S42fs exonic
chr12 76424952 CTG - PHLDA1:c.568_570del:p.190_190del exonic
chr12 9994450 GTT - KLRF1:c.377_379del:p.126_127del exonic
chr14 24646413 - AAG REC8:c.688_689insAAG:p.A230delinsEA exonic
chr14 53619494 - CGCCGC
DDHD1:c.323_324insGCGGCG:
p.S108delinsSGG
exonic
chr14 73957982 - C C14orf169:c.260_261insC:p.A87fs exonic
chr15 35230936 - GTTA AQR:exon10:c.718+2-TAAC splicing
chr15 93198687 GAGCTG - FAM174B:c.198_203del:p.66_68del exonic
chr16 138773 - G NPRL3:c.930_931insC:p.T310fs exonic
chr16 2059625 C - ZNF598:c.124delG:p.G42fs exonic
chr16 3602230 G - NLRC3:c.2318delC:p.A773fs exonic
chr17 26699368 - C SARM1:c.315_316insC:p.C105fs exonic
chr17 26727723 A - SLC46A1:c.1142delT:p.I381fs exonic
chr17 43192550 - C PLCD3:c.1622_1623insG:p.R541fs exonic
chr17 61660895 G - DCAF7:c.561delG:p.G187fs exonic
chr17 6555548 - G C17orf100:c.315_316insG:p.R105fs exonic
chr17 7470288 A - SENP3:c.1308delA:p.K436fs exonic
chr17 7750216 - ACCACC
KDM6B:c.791_792insACCACC:
p.P264delinsPPP
exonic
chr17 79614938 AACT - TSPAN10:c.682_685del:p.228_229del exonic
chr17 8725216 - G PIK3R6:c.1826_1827insC:p.S609fs exonic
chr18 19100762 - CTT GREB1L:c.5586_5587insCTT:p.L1862delinsLL exonic
chr18 43833704 - CTG C18orf25:c.757_758insCTG:p.G253delinsAG exonic
chr18 74090964 G - ZNF516:c.3106delC:p.P1036fs exonic
chr19 16268213 A - HSH2D:c.668delA:p.K223fs exonic
chr19 21299776 - AAT ZNF714:c.306_307insAAT:p.Y102delinsYN exonic
chr19 2340156 - C SPPL2B:c.824_825insC:p.P275fs exonic
chr19 30500143 TGA - URI1:c.798_800del:p.266_267del exonic
chr19 36258940 G - PROSER3:c.1193delG:p.G398fs exonic
chr19 41123095 - G LTBP4:c.3034_3035insG:p.V1012fs exonic
chr19 41173904 TTGCTG - NUMBL:c.1294_1299del:p.432_433del exonic
chr19 4954680 - C UHRF1:c.2015_2016insC:p.A672fs exonic
chr19 51835893 - G VSIG10L:c.2576_2577insC:p.A859fs exonic;splicing
chr19 56599452 GTC - ZNF787:c.1087_1089del:p.363_363del exonic
chr19 58718361 - G ZNF274:c.216_217insG:p.E72fs exonic
chr2 31805882 - G SRD5A2:c.88_89insC:p.P30fs exonic
chr2 95847047 GCG - ZNF2:c.348_350del:p.116_117del exonic
chr20 21186163 - G KIZ:c.987_988insG:p.R329fs exonic
chr20 278701 GGC - ZCCHC3:c.474_476del:p.158_159del exonic
chr20 32664865 - AGC RALY:c.642_643insAGC:p.A214delinsAS exonic
chr21 34166190 A T C21orf62:c.T543A:p.F181L exonic
chr3 12942852 C - IQSEC1:c.2976delG:p.L992fs exonic
chr3 14561629 - G GRIP2:c.1309_1310insC:p.P437fs exonic
chr3 16926642 A G PLCL2:c.A94G:p.T32A exonic
chr3 16926648 T G PLCL2:c.T100G:p.S34A exonic
chr3 50251835 - G SLC38A3:c.103_104insG:p.V35fs exonic;splicing
chr3 50306757 - C SEMA3B:c.85_86insC:p.H29fs exonic
chr4 140651610 TGC - MAML3:c.2277_2279del:p.759_760del exonic
chr4 177605086 CAT - VEGFC:c.1252_1254del:p.418_418del exonic
chr4 184367560 TGC - CDKN2AIP:c.723_725del:p.241_242del exonic
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chr22 37602586 - C SSTR3:c.1257_1258insG:p.X419delinsX exonic
chr5 140568035 - A PCDHB9:c.1143_1144insA:p.T381fs exonic
chr5 176930176 AGG - DOK3:c.555_557del:p.185_186del exonic
chr5 77745854 - A SCAMP1:c.730_731insA:p.I244fs exonic
chr6 160211649 GTT - MRPL18:c.30_32del:p.10_11del exonic
chr6 161519381 CTG - MAP3K4:c.3596_3598del:p.1199_1200del exonic
chr6 170871039 - GCA TBP:c.155_156insGCA:p.Q52delinsQQ exonic
chr6 28239933 - G ZSCAN26:c.236_237insG:p.C79fs exonic
chr6 30558478 - A ABCF1:c.2424_2425insA:p.X808delinsX exonic
chr7 128533516 - C KCP:c.940_941insG:p.G314fs exonic
chr7 128550685 C - KCP:c.46delG:p.G16fs exonic
chr7 149426307 - C KRBA1:c.1656_1657insC:p.A552fs exonic
chr7 150713903 - C ATG9B:c.2295_2296insG:p.E765fs exonic
chr7 28997597 - C TRIL:c.66_67insG:p.L22fs exonic
chr8 145106943 CC - OPLAH:c.3497_3498del:p.1166_1166del exonic
chr8 145738769 G - RECQL4:c.2296delC:p.P766fs exonic
chr8 30620844 - T UBXN8:c.625_626insT:p.X209delinsL exonic
chr8 38827187 C - PLEKHA2:c.1164delC:p.A388fs exonic
chr8 86126830 - ATTAAC
C8orf59:c.262_263insGTTAAT:
p.V88delinsVNV
exonic
chr9 123476563 GCGGCG - MEGF9:c.69_74del:p.23_25del exonic
Table A.28.: List of homozygous variants in genes expressed in skeletal muscle shared
by OPDM3, OPDM4 and OPDM5.
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